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Glucocorticoids have an effective anti-inflammatory, anti-proliferative and immuno-
modulatory activity. Therefore this class of drugs is used worldwide for the treatment of 
inflammatory diseases and to prevent rejection following organ transplantation. Inhaled 
glucocorticoids are the cornerstone treatment of asthma and advanced chronic obstructive 
pulmonary disease (COPD). The new long acting glucocorticoids mometasone and 
Ciclesonide have recently been introduced for the treatment of asthma.   
The aim of these studies is to assess the kinetics and molecular pathways of 
glucocorticoid receptor (GR) activation and traffic in human lung fibroblasts and bronchial 
smooth muscle cells. Furthermore the effects of new long acting glucocorticoids on GR 
activation, complex formation with the transcription factor C/EBP and its isoforms 
proliferation will be evaluated. 
Glucocorticoids enter the cytosol of cells by diffusion and bind to an intracellular specific 
receptor, the glucocorticoid receptor (GR), inducing a conformational change and leading 
thereby to its activation. The active GR translocates into the nucleus, where it binds to its 
cognate DNA recognition sequence, the glucocorticoid response element (GRE).  Often the 
activation of the GR is associated with a parallel activation of the transcription factor C/EBP-
, followed by de novo synthesis of p21(waf1/cip1), which in turn is mediating the GR dependent 
inhibition of the cell cycle. Both, GR and C/EBP- are necessary to induce and activate 
p21
(waf1/cip1) 
and to arrest the cell cycle at the transition from the G1- to the S-phase. 
Fibroblasts and bronchial smooth muscle cells are centrally involved in airway 
remodeling of patients with asthma and COPD. Therefore three cell types were chosen to 
assess the effect of the classical and new glucocorticoids on GR activation, cell proliferation 
and extracellular matrix deposition under different conditions. Four cell culture conditions 
were chosen to mimic different stages of inflammation: confluent cells without serum 
representing intact, not damaged tissue; confluent cells with 5% fetal calf serum to mimic 
early stages of inflammation; sub-confluent cells without serum to represent damaged tissue 
with no active inflammatory process; sub-confluent cells with 5% serum to represented tissue 
with active inflammation-induced lung tissue remodeling. 
The results showed that cell density and inflammation alter the localization and function 
of the GR. In sub-confluent cells dexamethasone activated the nuclear accumulation and DNA 
binding of the GR persistently, while in confluent cells its activity declined. In sub-confluent 
summary 
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cells, GR interacted with a 42 kDa C/EBP-α isoprotein, which resulted in an up-regulation of 
p21
(Waf1/Cip1)
 expression and suppression of proliferation. In confluent cells glucocorticoids 
induced p27
(Kip1)
 expression via p38 MAP kinase and a 52 kDa C/EBP-β isoprotein. 
Furthermore, p27
(Kip1)
 did not mediate the anti-proliferative effect of glucocorticoids, but 
simultaneous inhibition of p21
(Waf1/Cip1)
 and p27
(Kip1)
 unlocked contact inhibition in confluent 
cell cultures. 
The studies further showed that in lung fibroblasts the long acting steroid mometasone in 
contrast to ciclesonide or the short acting steroids dexamethasone, budesonide or fluticasone 
did not induce tachyphylaxis and had a preferable effect on airway remodeling. Mometasone 
maintained the increased GR activity significantly over 24 hours, compared to that induced by 
dexamethasone which peaked at 6 hours and declined thereafter. Similarly drug specific 
effects were observed for the expression of C/EBP- and p21(Waf1/Cip1). The anti-proliferative 
effect of mometasone was significantly stronger and long lasting compared to all other 
steroids. Similar anti-proliferative effects were observed in bronchial smooth muscle cells. 
Regarding airway remodeling we observed that mometasone, in contrast to all other steroids, 
did not further stimulate serum dependent synthesis and deposition of extracellular matrix and 
did not affect matrix metalloproteinase-2 and -9 expression or activity. Therefore this novel 
steroid will have a lower modulatory effect of tissue remodeling compared to the other 
steroids. Interestingly the long duration effects of the new glucocorticoid ciclesonide 
originated from the metabolism of the epithelial cells.   
     In conclusion, our findings suggest that the action of glucocorticoids differs under non-
inflammatory and inflammatory conditions in human lung fibroblasts and bronchial smooth 
muscle cells. Different doses of inhaled steroids might therefore be applied in patient with 
asthma and COPD dependent on the current status of inflammation in order to reduce side 
effects. The long acting glucocorticoid mometasone might help to reduce overall steroid 
dosage and might thereby reduce the risk of tachyphylaxis, enhanced tissue remodeling and 
other typical steroid side effects. Ciclosonide is a new long acting steroid, but its action on 
mesenchymal cells depends on the function of epithelial cells. 
These studies not only improve the understanding of the effect of different glucocorticoid 
on mesenchymal lung cells but might also help to find optional treatment doses. 
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Glucocorticoids, also known as glucocorticosteroids, cortcoisteroids or simply steroids 
are endogenously synthesized steroid hormones of the adrenal cortex and distributed by the 
blood circulation, regulating a variety of cell-, tissue- and organ-specific biological functions 
including immuno-modulation, metabolism, renal function, vascular leakage, cell growth, 
differentiation and death. Glucocorticoid synthesis is controlled by the hypothalamic–
pituitary–adrenal (HPA) axis. The major steroid hormones produced by humans are cortisol 
(hydrocortisone) and corticosterone which regulates stress and inflammatory response, lipid, 
carbohydrate and protein metabolism. Mineralocorticoids such as aldosterone act via their 
specific receptor and regulate mainly the water and salt balance in the kidney. Andogens and 
estrogens are steroids that regulate sexual development and function. Most synthetic steroids 
are designed to modulate the function of the first group of steroids, the cortisones.  
The glucocorticosteroid and its signaling pathway are among the most preserved 
mechanisms in evolution. Clinically, synthetic glucocorticoids represent a group of the most 
commonly prescribed drugs worldwide, and, are among the most potent anti-inflammatory 
drugs. They are also effectively used for their anti-inflammatory or immune-suppressive 
effects in asthma, dermatitis, rheumatoid arthritis, prevention of rejection in transplantation, 
and autoimmune diseases. Inhaled glucocorticoids have become the first line therapy in 
asthma. The molecular mechanisms how glucocorticoids suppress inflammation in asthma is 
based on their effect on gene transcriptions and signaling pathways (Barnes,1998;Barnes, 
2006;Coghlan et al., 2003;Adcock et al., 2006a).  
 
1.1 The Glucocorticoid Receptor (GR) 
Glucocorticoids mediate their effect via their intracellular receptor, the glucocorticoid 
receptor (GR), which belongs to a family of intracellular steroid hormone receptors that act 
primarily as transcription factors controlling gene activity. 
The cDNA of human glucocorticoid receptor (hGR), was first cloned in 1985 (Hollenberg 
et al., 1985), and later mapped to chromosome 5q31-32 (Theriault et al., 1989;Tsai and 
O'Malley, 1994). The GR protein possesses a modular structure consisting of three major 
domains—the N-terminal (NTD), DNA binding (DBD), and ligand binding (LBD). The GR 
gene has 10 exons spanning a 110 kb region. The 184 nucleotides of exon 1 represent solely 
the 5‘-untranslated region. Exon 2 (1197 bp) encodes most of the receptor N-terminus, 
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including the constitutive AF1 transactivation domain. The two zinc-finger motifs involved in 
DNA-binding are separately encoded by exon 3 (167 bp) and exon 4 (117 bp). Five exons 
(exons 5, 6, 7, 8, 9) together make up the ligand-binding domain and ligand-dependent AF2 
as well as the 3‘-untranslated regions. The promoter of the GR lacks a TATA box for 
transcriptional activation and it also does not have a CCAAT motif in the 5‘-flanking region. 
Instead, multiple GC boxes, activator protein-1 (AP-1), AP-2, Sp1, cAMP-responsive 
elements (CRE), Yin Yang1 (YY1), nuclear factor-kappa B (NF-κB)  and several tissue-
specific transcription factor-binding sites have been identified that regulates its expression. 
This information is consistent with the notion that GR is constitutively expressed in virtually 
every cell type, but with a tissue-specific pattern (Haché et al., 1999;Necela and Cidlowski, 
2004;Kumar and Thompson, 2005;Tsai and O'Malley, 1994;Hayashi et al., 2004a) (figure.1). 
Alternative splicing of pre-RNA generates two different isoforms of hGR: hGRα and hGRβ.  
In addition, there exists a membrane specific GR (Bartholome et al., 2004; Jain et al., 
2005). The classic hGRα, consists of 777 amino acids and is expressed by all cell types. The 
hGRβ is of smaller size generated by splicing of the last exon, resulting in a protein of 742 
amino acids that diverges at its C terminus, and the final 15 amino acids of the C-terminal 
domain are unique to hGRβ. The hGRβ seems to act mainly as a dominant negative factor that 
blocks the function of hGRα as a transcription factor. The ratio of GRα:hGRβ expression is 
indeed critical to the glucocorticoid responsiveness of various cells. This ratio can be altered 
by changing the expression level of the hGRα, or the hGRβ, or of both receptors. Higher 
ratios of hGRα:hGRβ correlate with glucocorticoid sensitivity, while lower ratios correlate 
with glucocorticoid resistance (Lewis-Tuffin and Cidlowski, 2006).  
 
 
Figure 1. A diagram of the molecular nature of the human glucocorticoid receptor. Adapted 
from (Necela and Cidlowski, 2004) 
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1.2 GR signal transduction 
The hGR is a 94 kDa protein, and the inactive hGR is located in the cytoplasm, where it 
is complexed with heat shock proteins (HSP) 70, HSP90, and the immunophylins p59, 
phosphoprotein p23 and  FKBP51 (Haché et al., 1999;Pratt et al., 1992;Pratt et al., 2006). The 
GR is activated by binding of a glucocorticoid inducing a structural transformation, 
disassembly of the multi-protein complex, followed by subsequent homodimerisation with a 
second GR molecule. The GR-dimer is then linked via FKBP51 for trafficking along 
microtubules which translocates the GR-complex into the nucleus (Haché et al., 1999;Umland 
et al., 2002;Davies et al., 2002). In the nucleus, the dimerized GR binds into the major groove 
of the DNA through its central zinc finger DNA-binding domain, which recognizes distinct 
palindromic DNA sequences, termed glucocorticoid response elements (GREs). The GRE 
consensus sequence is 5‘-TGTACAnnnTCTTGT-3‘(where ―n‖ represents any nucleotide) 
(Almawi and Melemedjian, 2002), which is usually located in promoters of glucocorticoid 
responsive genes. Binding of the GR to the GRE results in inducing conformational change 
within the receptor (Starr et al., 1996). The allosteric interaction promotes the recruitment of 
several co-activator complexes critical for remodeling of chromatin structure. However, many 
GR responsive genes do not have a GRE, but the GRE interferes with several other 
transcription factors and/or coactivators and thereby affects the transcription of this GRE-less 
genes. The binding of the GR complex to the GRE can either stimulate or silences the 
respective genes (Adcock and Lane, 2003). The copy number of the GRE differs among gene 
promoters as does their sequence in a promoter. In addition the distance of the GRE to other 
transcription factor binding sites is important for the effects of glucocorticoids on gene 
activity. 
The GR interacts with transcription initiation factors such as the cAMP response 
element–binding protein (CREB), CREB-binding protein (CBP/p300) and the p300/CBP 
associated factor (p/CAF). These proteins contain intrinsic histone acetylase activity, which 
resulted in opening up to the chromatin structure of the coiled DNA, to allow binding of RNA 
polymerase II and initiates gene transcription. Several transcription factors interact with CBP, 
including CREB, NF-kB and AP-1 and these coactivators acetylate lysine residues in core 
histones to induce nucleosomal rearrangement of the DNA (Smirnov, 2002;Bruna et al., 
2003;Jenkins et al., 2001;Deroo and Archer, 2001). 
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Other coactivator complexes such as steroid receptor coactivator-1, p/CIF, SWI/SNF, and 
GRIP1/TIF2/NcoA-1 (GRIP: glucocorticoid receptor interacting protein) further contribute to 
this chromatin-remodeling process (Smirnov, 2002;Bruna et al., 2003;Jenkins et al., 
2001;Deroo and Archer, 2001). Nucleosomal rearrangement leads to promoter accessibility 
and the recruitment of the basal transcriptional machinery, including TATA box-binding 
protein (TBP), TBP-associated factors, and RNA polymerase II. The concerted assembly of 
these factors results in the stimulation of selective gene transcription.  (Davies et al., 
2002;Smirnov, 2002;Bruna et al., 2003;Jenkins et al., 2001;Deroo and Archer, 2001;Pelaia et 
al., 2003;Adcock et al., 2006a). An overview of this transcription complex and the role of the 
GR is shown in figure 2 (Pelaia et al., 2003). 
 
1.3 GR signal pathway cross talking with other transcription factors 
In addition to direct binding to GRE promoter elements, the GR also works through its 
association with other transcription factors. Thereby the GR can become involved in many 
transcription factor signalluing pathways and expand the GR function through cross talking 
with other signal pathways that makes the evaluation of such a signal network complicated. 
For example, in the mouse liver the presence of exogenous glucocorticoid modulates over 
1,300 genes and here the GR binds to more than 300 promoters, but only the activity of 53 
genes is functionally regulated upon the direct ligand-bound GR (Phuc et al., 2005).  
The activated GR interacts with other transcription factors including C/EBP-α, C/EBP-β, 
Stat3/5, NF-κB, or AP-1(Rogatsky and Ivashkiv, 2006a;Bruna et al., 2003;Zhang et al., 
1997;Floyd and Stephens, 2003;Aljada et al., 1999;Gotoh et al., 1997;Adcock et al., 
1996a;Borger et al., 2002;Cha et al., 1998;Rüdiger et al., 1999a). This protein-protein 
interaction of the GR with other transcription factors does not need the translocation of the 
active GR into the nucleus and occurs in the cytosol (Wikström, 2003). Table 1 provides a 
summary of genes, which are controlled by the GR. 
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Figure 2.  Nuclear receptors can interact with coactivator complexes including CBP (CREB-binding 
protein)/p300 and p/CAF (p300/CBP associated factor) that possess histone acetyltransferase activities, p/CIP 
(p300/CBP co-integrator associated protein), SRC-1 (steroid receptor coactivator 1), and the SWI/SNF complex 
which possesses ATP-dependent chromatin remodeling activities. All these complexes may act in concert to 
relieve chromatin-mediated gene repression, with the TRAP (thyroid hormone receptor associated 
protein)/GRIP (glucocorticoid receptor interacting proteins)/ARC (activated recruited cofactor) complex 
functioning to recruit the core transcription machinery. The latter includes the TATA box-binding protein (TBP), 
the TBP associated factors (TAFs), the general transcription factors IIA, IIB, IIE, IIF, IIH, IIJ, and the enzyme 
RNA polymerase II (Pol II). Nuclear receptors can also interact with the corepressors N-CoR (nuclear receptor 
corepressor) and SMRT (silencing mediator of retinoid and thyroid hormone receptor) thus leading to the 
recruitment of the mSIN3/HDAC (histone deacetylase) corepressor complex, possessing histone deacetylase 
functions. This corepressor complex can thereby inhibit gene transcription by counteracting the actions of the 
coactivator complexes containing histone acetyltransferase activities.  
 
1.3.1 NF-κB  
 
NF-κB is assumed to be one of the pivotal transcription factors contributing to synthesis 
of pro-inflammatory factors in inflammatory diseases (Barnes and Adcock, 1997). NF-κB 
regulates several inducible genes, including nitric oxide synthase (iNOS), and the inducible 
form of cyclo-oxygenase (COX-2). It stimulates chemotactic cytokines (chemokines) such as 
interleukin (IL)-8 and eotaxin, and adhesion molecules such as ICAM-1 and VCAM-1 that 
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play a key role in inflammatory cell recruitment (Barnes and Adcock, 1998;Beato et al., 
1996). Inactive form of NF-κB is located in cytoplasm and complexes with an inhibitory 
protein, IκB. Upon cell activation, IκB kinase-2 (IKK2) phosphorylates IκB, and after 
ubiquitination, the proteasome rapidly degrades IκB, releasing free form of NF-κB, NF-κB 
itself has two subunits, a p65 (or named Rel A) subunit and p50 subunit, both of which are 
members of the Rel family (Karin, 1999;Hart et al., 1998). Free NF-κB enters the nucleus as a 
p50-p65 heterodimer that binds to a κB recognition sites in the 5'-promoter (upstream) region 
of inflammatory genes, stimulating their synthesis. The p50-p65 heterodimer NF-κB can also 
bind to CBP or PCAF, this binding resulting in acetylation of lysines in core histone-4 and 
Table：The effect of glucocorticoids on gene transcription, adapted from (Barnes, 
2006;Hayashi et al., 2004b) 
Increased transcription Decreased transcription  
Annexin 1 /lipocortin-1( phospholipase A2 inhibitor) 
 ß2-Adrenergic receptor  
Secretory leukoprotease inhibitor(SLPI) 
CC10 (phospholipase A2 inhibitor)  
 IL-1 receptor antagonist 
 IL-1 receptor type II (decoy receptor) 
 IκB-α 
 GILZ  
 MKP-1(MAP Kinase phosphatase1) 
 IL-10 (indirectly) 
CD163(scavenger receptor) 
 Cytokines: 
 
    IL-1 to IL-6, IL-9, IL-11 to IL-13,  
    IL-16 to IL-18, TNF-α, GM-CSF, SCF  
 
 Chemokines:  
    IL-8, RANTES, MIP-1α, MCP-1, MCP-3,  
    MCP-4, eotaxins 
 
Adhesion molecules:   
    ICAM-1, VCAM-1, E-selectin 
Inflammatory enzymes:  
     iNOS, inducible COX-2, cPLA2 
Inflammatory receptors:   
    Tachykinin NK1 and NK2 receptors, 
Bradykinin   
    B2 receptors 
 
Peptides:  
      Endothelin-1 
 
changes the structure of the DNA coil opening it up to give access to other transcription 
initiating proteins (Cayrol and Ducommun, 1998;Ito et al., 2000), it may need both 
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mechanisms to activate the transcription of a pro-inflammatory gene histone acetylation and 
promoter binding (Karin and Chang, 2001;Barnes and Adcock, 1995;Barnes, 1998;Karin and 
Chang, 2001) (see figure.2).  
Glucocorticoids inhibit histone acetylase (HAT) activity directly and specifically recruit 
histone deacetylase (HDAC)-2, which reverses histone acetylation leading to the suppression 
of inflammatory genes (Adcock et al., 2004;Barnes and Adcock, 1995;Karin and Chang, 
2001). Glucocorticoids inhibit NF-κB activity also by induce IκB synthesis and thus 
antagonise NF-κB activation (Auphan et al., 1995;Scheinman et al., 1995b;Scheinman et al., 
1995a).  
 
1.3.2 β2- Adrenergic receptor 
The human β2-Adrenergic receptor (β2-AR) gene is situated on the long arm of 
chromosome 5 and encodes for an intronless gene product of approximately 1200 base pairs, 
which is classically identified in cardiac and airway smooth muscle cells. β2-AR is one of the 
G protein–coupled receptors, and has 7 trans-membrane spanning a-helices. The β2-AR 
oscillates between activated and inactivated forms, thereby controlling its function. (Johnson, 
2006). The coupling of the β2-AR to adenylate cyclase occurs through a trimeric G protein, 
consisting of α-subunit (which stimulates adenylate cyclase) and βγ-subunits (which 
transduce other signals). Activation of the β2-AR by β2-agonists causes the α-subunit of the 
associated G protein to dissociate and couple with adenylate cyclase, leading to enhanced 
production of cAMP, a very important second signal messenger and also stimulates of PKA. 
PKA induces phosphorylation of other proteins and uncouples the G protein from the β2-AR. 
The phosphorylated receptor, with its residual βγ-subunits, then couples to Gi which binds to 
β-arrestin, and then acts as an assembly scaffold for Src, SOS, and RAS, which in turn 
activates the MAPK pathway (Adcock et al., 2002;Johnson, 2006;Adcock et al., 1996b).  
In primary human lung fibroblasts and smooth muscles, salbutamol and salmeterol 
induced the nuclear accumulation of the GR and enhanced GR-GRE binding in the absence of 
steroids. The translocation of the GR into the nucleus by β2-agonists was less effective than 
by a steroid and was PKA dependent (Eickelberg et al., 1999). Long-acting β2-agonists may 
affect GR nuclear localization priming of GR functions within the nucleus by modifying GR 
or GR-associated protein phosphorylation. Furthermore, PKA phosphorylates serine 276 of 
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the p65 subunite of NF-κB and thus enhance NF-κB-GR cross-talking (Haske et al., 1994). 
However, long term administration of β2-agonists in vivo down-regulates the expression of β2-
AR, while glucocorticoid treatment increased the number of β2-AR in the human lung (Davies 
and Lefkowitz, 1984;Davies and Lefkowitz, 1981).  Treatment with β2-agonists inhibits cell 
proliferation, and needs the activation of negative cell cycle regulator p21
(waf1/cip1) 
gene 
(Rüdiger et al., 1999b). 
In regard to the effect of β2-agonists on GR activation it is important to note that cAMP 
activates the transcription of the GR promotor (Penuelas et al., 1998). cAMP activates protein 
kinase A (PKA), which phosphorylates a transcription factor CREB that binds to a cAMP 
response element (CRE) in the promoter region of certain genes. CREB is a member of large 
family of CRE binding proteins, including members of the ATF family. As described above 
CREB binds to CBP that acts as a co-activator molecule that binds to the TATA box and 
initiates transcription. CREB may be counteracted by another transcription factor called CRE 
modulator (CREM) that may block the effects of CREB on CRE.  
CREB also appears to be important in the regulation of β2-AR expression as it is activated 
by relatively high concentrations of β2-agonists in the lung and may play a role in the down 
regulation of β2-AR after chronic treatment with β2-agonists. CREB has a negative effect on 
AP-1 and GR, and high concentrations of β2-agonists inhibit the binding of GR to the GRE 
sequence. This may interfere with the anti-inflammatory effects of steroids and may account 
for the deleterious effects of high dose inhaled β2-agonists in patients with asthma. The cAMP 
responsiveness can occur in the absence of CREB when C/EBP-α functionally substitutes for 
CREB. This finding suggests that the mechanism whereby C/EBP-α mediates constitutive 
transactivation is distinct from that whereby it mediates cAMP responsiveness (Penuelas et 
al., 1998). 
 
1.3.3 The effect of the GR on p38 MAPK pathway  
The intracellular signal transducing protein p38 MAPK is activated by inflammatory 
stress through activation of MAPK kinase (MKK)-3 and -6. Activated p38 MAPK 
phosphorylates MAPK-activated protein kinase (MAPKAPK)-2, which stabilises mRNA 
encoding several inflammatory proteins, such as tumor necrosis factor (TNF)-α, IL-1β, IL-6, 
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IL-8, GM-CSF and COX-2 (Smoak and Cidlowski, 2004;Page and Hershenson, 
2000;Szatmary et al., 2004). All these mRNA are characterized by adenine–uracil-rich 
elements (AREs) in the 3‘-untranslated region, which makes the mRNA unstable and rapidly 
degraded. ARE-binding proteins (AREBPs) stabilize these proteins and may be activated by 
MAPKAPK-2(Page and Hershenson, 2000;Szatmary et al., 2004).  
Glucocorticoids induce the expression of MAPK phosphatase (MKP)-1, which inhibits 
p38 MAPK and, thus, prevents the stabilization of multiple inflammatory proteins (Pelaia et 
al., 2003;Barnes, 2006). The pattern of MAPK expression, activation and pharmacological 
modulation differs among the various cell types and tissues when exposed to endogenous or 
synthetic glucocorticoids, and the ability of glucocorticoids to block MAPK phosphorylation 
is at least in part cell-type or stimulus-specific. Glucocorticoid-induced MAPK inhibition 
seems to be mediated by an increased expression, as well as by a decreased proteolytic 
degradation, of the MAP kinase phosphatase-1 (MKP-1) (Kassel et al., 2001). 
1.3.4 TGF-β signal 
The transforming growth factor-β (TGF-β) and the glucocorticoid signaling pathways 
interact both positively and negatively, thereby regulating physiological and pathologic 
processes The promoter region of the human TGF-β1 gene revealed a consensus GRE (5‘-
AGAACA) located from (-1081) to (-1086) base pairs (Parrelli et al., 1998). GR regulated 
TGF-β transcriptional activation involved both Smad3 and Smad4 C-terminal activation 
domains. GR interacts with Smad3 both in vitro and in vivo (Song et al., 1999;Chou et al., 
2003). The molecular mechanism of TGF-β to exert its effect involves the activation of Smad 
proteins that control gene transcription directly or by the cooperation with other transcription 
factors, TGF-β has been to found to interact with the GR and thereby enhanced the 
glucocorticoid response of the mouse mammary tumor virus promoter (Aurrekoetxea-
Hernandez and Buetti, 2000;Aurrekoetxea-Hernandez and Buetti, 2004). This effect may be 
explained by the observation that TGF-β increased glucocorticoid binding and signaling 
through a Smad 2/3- and AP-1-mediated mechanism (Peltier et al., 2003).   
The interaction of the GR with TGF-β can occur on several levels and may include a 
feedback mechanism. The LBD  of GR, but not the DNA-binding domain or the N-terminal 
activation domain, is required for GR-mediated transrepression of TGF-β transactivation (Li 
et al., 2003). However, TGF-β can also antagonize the growth inhibitory properties of GR by 
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blocking GR transactivion of various promoters through a mechanism involving 
transcriptional repression by DNA-bound AP-1 (Periyasamy and Sanchez, 2002).  
Furthermore, TGF-β controls GR gene transcription through Smad2/3 by different 
mechanisms. First, Smad2/3 might interact with a putative Smad binding element (CAGACA) 
in the GR gene promoter. Second multimeric Smad-AP-1 complexes might interact with a 
single AP-1 site in the GR gene promoter. Third, Smad2/3 might also affect the transcription 
of genes encoding proteins that control indirectly GR gene expression, and TGF-β1 might 
increase the expression of the HSP 90, which is bound to the inactive GR and shapes the 
hormone binding domain into a ligand binding conformation (Bellocq et al., 
1999;Aurrekoetxea-Hernandez and Buetti, 2004).  
 
1.4 Cell cycle control and p21(WAF1/CIP1)  
Cyclins are the regulatory subunits of the holoenzyme cyclin dependent kinase (CDK) 
complexes, which control the progression through cell cycle checkpoints by phosphorylating 
and inactivating target substrates. The Cyclin family is divided into two main classes: 
1. G1-phase cyclins include cyclin C, D1-3, and E, and their accumulation is rate-limiting 
for progression from the G1- to S-phase.  
2. G2-phase cyclins, which include cyclin A and cyclin B, are involved in the control of 
G2/M-phase transition and control mitosis.  
In different phases of the cell cycle, CDK4/6 bind to cyclin D, CDK2 binds to cyclins E or 
A and CDK1 binds to cyclins A or B (Martin et al., 2005b;Ortega et al., 2002b). The cyclins 
bind to and activate the CDKs, which leads to the phosphorylation of the tumor suppressor 
protein, pRb and thus to the inhibition pRB. pRb the progress from the G1- to S-phase, at least 
in part by repressing the activity of the E2F transcription factors known to promote cell 
proliferation. Both the D-type cyclins and their partner kinases CDK4/6 activity is regulated 
at multiple levels including negative control by two families of CDK inhibitors. While 
members of the INK4 family (p16INK4A, p15INK4B, p18INK4C, p19INK4D) interact 
specifically with CDK4 and CDK6, the CIP/KIP inhibitors p21
(waf1/cip1)
, p27KIP1 and 
p57KIP2 inhibit a broader spectrum of CDK (Golias et al., 2004). The interaction between 
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p16INK4A, cyclin D/CDK, and pRb/E2F together constitute a functional unit collectively 
known as the ‗pRb pathway‘. pRb is subject to different sets of multiple phosphorylations by 
cyclinD: CDK4/6 and cyclinE: CDK2. The E2F binding of p107, p130 and pRB, all is also 
inhibited by phosphorylation. Phosphorylation of E2F and/or DP by Cyclin A: CDK2 inhibits 
the E2F-DP interaction, releasing a free E2F and thus turn on transcription (Genovese et al., 
2006).  
The cyclin-dependent kinase inhibitor p21
(waf1/cip1)
 is a major
 
player in cell cycle control 
and it is mainly regulated at the
 
transcriptional level. Which belongs to the Cip/Kip family of 
cdk inhibitors, it mainly inhibits the activity of cyclin/cdk2 complexes
 
and negatively 
modulates cell cycle progression (Waga et al., 1994;Harper et al., 1993;Martin et al., 
2005a;Ortega et al., 2002a). In addition, p21
(waf1/cip1) 
can bind to proliferating cell nuclear 
antigen (PCNA) thereby blocking
 
DNA synthesis. A large varity of factors  are known to 
activate p21
(waf1/cip1)
 including: p53, SP-1/SP-3, Smads, AP-2, STAT, E2F-1/E2F-3, CEBP-α 
and -β (Cram et al., 1998;Barnes, 2006), Glucocorticoids achieve their anti-proliferative 
function by interaction with theses factors. GR can form a complex with CEBP-α, and induces 
the translocation of the complex into the nucleus, where the complex through protein 
interactions of CEBP-α with p21(waf1/cip1) inhibits CDK2, and this mechanism is independent 
of transcriptional activity (Harris et al., 2001). CEBP-α and the GR also work by binding to 
the transcriptional responsive elements in the promoter of p21
(waf1/cip1)
, inducing its 
transcription and thereby mediating cell cycle arrest (Ramos et al., 1996;Rüdiger et al., 
2002;Gotoh et al., 1997;Cha et al., 1998). In addition, p21
(waf1/cip1) 
also exerts its functions by 
directly blocking the ability of PCNA to activate DNA polymerase-, the principal replicative 
DNA polymerase, thus inhibit DNA replication (Waga et al., 1994). Previously, in our 
laboratory it was shown that GR activation by glucocorticoids and β2-agonists led to the 
subsequent activation of p21
(waf1/cip1) 
thereby inhibiting the proliferation of human lung 
fibroblasts, pulmonary vascular and bronchial smooth muscle cells   (Eickelberg et al., 
1999;Roth et al., 2000;Roth et al., 2002;Roth et al., 2004). Among the other transcription 
factors that interact with the p21
(waf1/cip1)
 gene promoter, STAT is very important (Almawi et 
al., 1996;Almawi and Melemedjian, 2002;Rogatsky and Ivashkiv, 2006b). 
1.5 Scope of this Thesis: 
The use of synthetic glucocorticoids in asthma and COPD therapy is widespread due to their 
powerful anti-inflammatory, anti-proliferative and immuno-modulatory activity. However, 
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long-term use of these drugs can result in severe side effects. Long time inhaled at high 
doseage impaired growth of children, decreased bone mineral density, induced skin thinning 
with the consequence of bruising, and cataract development (Rosen and Miner, 2005). The 
search for novel glucocorticoids that have reduced side effects is being driven by the 
identification of new mechanisms of action of glucocorticoids and the GR. Understanding of 
the mechanism that regulates a specific gene by the glucocorticoid-signaling pathway may 
lead to more specifically targets for therapy, help to prevent unwanted side effects and help to 
provide some practical implications for the clinical use of glucocorticoids 
 
Most side effects of glucocorticoids appear to be due to GR DNA binding and through the 
regulation of gene activity. Whereas the anti-inflammatory effect of this class of drugs is now 
adays assumed to be regulated pre-dominantly by the inhibition of inflammatory gene 
expression by interference of the GR with NF-kB activity and other pro-inflammatory 
transcription factors, therefore through a non-direct DNA binding mechanism which may be 
mediated via inhibition of HAT activity and HDAC recruitment (Smoak and Cidlowski, 
2004;Adcock et al., 2004;Adcock et al., 2006a;Miner et al., 2005). This new aspect of GR 
action has led to a search for novel corticosteroids that selectively trans-repress gene activity 
without significant trans-activation or cis-repression, thus reducing the potential risk of side 
effects. 
The increased understanding of transcription factors that are associated with the GR has given 
new insights into the pathophysiology of inflammatory disease such as asthma, and opened an 
opportunity for the development of new anti-asthma treatments. The steroids used in asthma 
therapy today, such as fluticasone propionate and budesonide, appear to have more potent 
trans-repression than trans-activation effects, which may account for their selection as potent 
anti-inflammatory agents (Jaffuel et al., 2000).  
One of the most important implications of research on transcription factors is that of multiple 
and complex interactions between these proteins are possible and this leads to the so called 
cross talk between different signal transduction pathways. Transcription factors and their 
inhibitors or activators, maybe also the potential drug target (Roth and Black, 2006;Adcock 
and Caramori, 2004;Adcock et al., 2006b). However, when the targeted transcription factors 
are not cell- or tissue-specific their long-term general suppression or over-expression may 
Introduction 
 - 26 - 
potentially cause severe side effects as well. It is well known that prolonged and continuous 
treatment of patients with corticosteroids leads to unwanted side effects, such as osteoporosis. 
A delivery system of transcription factor inhibitors and/or activators to a specific cell type 
would mean a tremendous improvement for drug targeting (Roth and Black, 2006).  
More developments in the molecular mechanism of GR signal transduction provided 
theory supports for clinically therapy, combination of drugs that act on different transcript 
factors or pathways that may work together co-operatively.  In asthma, glucocorticoids with 
β2-agonist treatment, the synergistic interaction so effective than either drug alone (Roth et 
al., 2002). In this study, it was attempted to describe the GR distribution and activation by 
different long acting steroids in inflammation conditions. 
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AIM OF THE THESIS 
 
This thesis aims to assess the kinetics of the GR activation and traffic in human lung cells 
under different conditions of growth and inflammation. Furthermore the effect of the new 
long acting glucocorticoids mometasone and ciclesonide on GR activation, complex 
formation and cell growth will be evaluated. 
 
Specific aims of the thesis will address the following topics: 
 
─determination of the distribution and activation of the GR under different cell cultures 
conditions including cell density and inflammation. 
 
─Characteration of the conditions of the GR with the anti-proliferative transcriptor factor 
C/EBP and its isoforms under different cell culture conditions. 
 
─Comparison of the expression and activation of the GR the new long acting glucocorticoids 
mometasone and Ciclesonide with classical steroids including assessment of subsequent anti-
proliferative pathways. 
 
─Analysis of the effects of mometasone on extracellular matrix production and regulation by 
metalloproteinase. 
 
─Evaluation of the mechanisms of activation and metabolism of Ciclesonide. 
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CHAPTER 2   
Cell differentiation modifies the composition and function of the 
glucocorticoid receptor - C/EBP complex 
 
 
When Glucocorticoids passively enter into the cytosol of the cells, it binds to GR and 
format a complex to enter the nucleus and then binding to GRE to control the cell activity. In 
our previous works, we found that GR can form a complex with C/EBP-, which is essential 
to stimulate p21
waf1/cip1
 expression thus the GR mediates its anti-proliferative effect in most 
human cell types. 
Inflammation of the lung is characterized by vessel leakage and infiltration of serum into 
the surrounding tissue, thereby also exposing mesenchymal cells in undamaged tissue areas to 
serum containing pro-inflammatory factors. In this study low cell density and serum was used 
to mimic the condition of inflammation in which fibroblasts have to fill wounds to 
reconstitute damaged tissue. In this part of the studies I investigated the effect of cell density 
and the presence of serum on the activation and cell compartmental translocation of the GR in 
response to dexamethasone in cultures of primary human lung fibroblasts. I further 
investigated the role of the GR and C/EBP-α and –β on expression and complex formation in 
regard to their effect on two major anti-proliferative proteins p21
(Waf1/Cip1
) and p27
(Kip)
, and 
their activation by dexamethasone.  
 
2.1 OBJECTIVES: 
1. Is the GR distribution different at different cell culture conditons? 
2. Does the serum affect the GR distribution and activation? 
3. Does serum affect dexametasone-induced GR distribution and activity? 
4. Does the cell density and cell differentiation affect the GR interaction with C/EBP 
isoforms and subsequently the action of p21/p27? 
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2.2.1 Abstract 
The glucocorticoid receptor is a major control factor for cell proliferation, cell 
differentiation and inflammation. Our knowledge about the glucocorticoid receptor is focused 
on its function as a transcription regulator. However, cells are not always responding to 
steroids in the same way or develop tachyphylaxis or resistance. The mechanism underlying 
such a modified steroid response is not well understood and may depend on the 
microenvironment of the cells or on the stage of their differentiation. Therefore we studied the 
effect of cell density and inflammatory conditions on the expression, compartmentalisation, 
activation, and the anti-proliferative function of the glucocorticoid receptor in primary human 
lung fibroblast cultures. In sub-confluent cells the glucocorticoid receptor was located peri-
nuclear, while in confluent cells it was ubiquitously expressed. Serum stimulation up-
regulated the level of glucocorticoid receptor mRNA and protein under all conditions. In sub-
confluent cells dexamethasone activated the nuclear accumulation and DNA binding of the 
glucocorticoid receptor persistently, while in confluent cells its activity declined after 6 hours. 
In sub-confluent cells, but not in confluent cells, the glucocorticoid receptor interacted with a 
42 kDa, but not the 30 kDa C/EBP- isoprotein, which resulted in an up-regulation of 
p21
(Waf1/Cip1)
 expression and suppression of proliferation. In confluent cells glucocorticoids 
induced p27
(Kip1)
 expression via p38 MAP kinase and a 52 kDa C/EBP-isoprotein. However, 
p27
(Kip1)
 did not mediate the anti-proliferative effect of glucocorticoids, but simultaneous 
inhibition of p21
(Waf1/Cip1)
 and p27
(Kip1)
 unlocked contact inhibition in confluent cell. Our 
results indicate that cell density and inflammation alter the localisation and function of the 
glucocorticoid receptor. (250)  
Keywords: glucocorticoid receptor, primary human lung fibroblasts, proliferation control, 
tissue remodeling 
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2.2.2 Introduction 
Glucocorticoids are expressed in virtually every known cell type and controls cell 
differentiation, organ development, and function. Glucocorticoids also regulate immune 
response, fat metabolism, renal function, and vascular leakage in most organisms (1, 2). 
Glucocorticoids bind to the inactive glucocorticoid receptor (GR) in the cytosol and induce 
the restructuring of the GR-multi protein complex. Two active GR molecules form a dimer 
that couples to FKBP52 and dynein and which mediate the transported into the nucleus (3, 4). 
In the nucleus the GR-dimer binds to a DNA sequence assigned as the glucocorticoid 
response element (GRE) and can either stimulate or silence genes (1, 5).  
Interestingly, treatment with the steroids significantly down-regulated GR expression 
which suggests a self limiting control mechanism and may result in tachyphylaxis in long 
term steroid treatment (6-8). Beside its action as a transcription factor the GR mediates its 
effect also by binding to and modifying the function other transcription factors including 
C/EBP-, -, Stat1/5, NFB, or AP-1 (9-14). Specifically of interest for proliferation control 
are the complexes formed by the GR with the transcription factors C/EBP- or –as they are 
essential to initiate the expression of  p21
(Waf1/Cip1)
 and thereby mediate the anti-proliferative 
effect of steroids (10, 15, 16). Fibroblast proliferation is inhibited by glucocorticoids also via 
the activation of p21
(Waf1/Cip1)
 which requires C/EBP- activity (15, 17, 18). However, 
glucocorticoids do not always block proliferation in fibroblasts and the reason for this is 
unknown (19-21). The anti-proliferative efficacy of glucocorticoid may vary with the 
mitogenic stimulus (18), might be a species specific effect (20), or be affected by the organ of 
origin of the fibroblasts, or the underlying disease (19, 21). We described earlier that a cell 
type specific lack of C/EBP-in bronchial smooth muscle cells of asthma patients is 
responsible for the enhanced proliferative capacity of this cells and possibly leads to airway 
muscle cell hyperplasia in asthma (22-24). In addition to airway smooth muscle hyperplasia 
the airway wall of asthma and COPD patients is also characterised by increased fibroblast 
proliferation and extracellular matrix deposition in the lamina propria (2, 25). The effect of 
steroids on these pathologies is controversial discussed and their effect may depend on drug 
dosage, length of therapy, and severity of the disease (2, 26). We have recently demonstrated 
that the effect of steroids on extracellular matrix and collagen deposition is modified by the 
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presence of serum in human lung fibroblasts. In resting cells or in the presence of TGF-1 
steroids down-regulated the deposition of extracellular matrix, while in the presence of serum 
(5%) steroids further increased extracellular matrix deposition (26).  
In regard to cell proliferation control it is important to note that cell density and the 
presence of mitogen modified the expression and function of p21
(Waf1/Cip1)
 in fibroblast (27, 
28). Furthermore, translocation of non-activated p21
(Waf1/Cip1)
 into the nucleus of pancreatic 
fibroblasts was associated with differentiation into myo-fibroblasts which expressed muscle 
cells actin and were more susceptible to apoptotic signals (29). In an animal model for 
adipocyte differentiation cell density and serum affected the function of dexamethasone and 
the expression of C/EBP- and – (30). Taking into account that at least active C/EBP- is 
required for the anti-proliferative effect of glucocorticoids we hypothesized that cell density, 
as well as mitogen, and cell differentiation change the function of the GR. Furthermore, 
glucocorticoids also activate a second cell cycle control protein, p27
(Kip)
, but its role in the 
drug‘s effect is unclear and may be cell type or species specific (15, 31).  
Therefore, we investigated the effect of cell density and the presence of serum on the 
activation and translocation of the GR in response to dexamethasone in cultures of primary 
human lung fibroblasts. We further investigated the role of the GR and C/EBP- and – on 
expression of two major anti-proliferative proteins p21
(Waf1/Cip1
) and p27
(Kip)
, and their 
activation by dexamethasone.  
 
2.2.3 MATERIAL AND METHODS 
Chemicals: All chemicals were from Calbiochem (La Jolla, USA) if not otherwise notified. 
Complete protease inhibitor are: Roche Diagnostics (Basel, Switzerland), gradient poly-acryl 
amid gels (PAGE): Biorad (Hercules, USA). Minimal essential medium (MEM), RPMI 1640, 
phosphate buffered saline (PBS w/o Ca
2+
 and Mg
2+
): Cambrex Bio Science Verviers 
(Verviers, Belgium), PVDF-membranes: Millipore (Bedford, USA), Ponceau: Sigma (Buchs, 
Switzerland), enhanced chemiluminescence (ECL): Pierce (Rockford, IL, USA) and X-ray 
films: Kodak (Eastman Kodak, Rochester, USA). Antibodies and small inhibitory (si) RNAs: 
Santa Cruz Biotechnology (Santa Cruz, USA). Cy3-labelled goat anti rabbit-IgG: Jackson 
ImmunoResearch Laboratories, USA. GRE oligonucleotides: Affinity Bioreagents Inc 
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(Golden, USA), all other DNA oligonucleotides MWG-Biotech GmbH (Ebersberg, 
Germany).  
Fibroblast culture: Primary fibroblasts were established from lung tissue samples after 
written consent and approval by the ethical committee (University Hospital Basel). 
Fibroblasts were grown in RPM1-1640 supplemented with 10 % fetal calf serum (FCS) and 1 
% MEM vitamins. All experiments were performed between cell passage two - six. 
Fibroblasts were seeded (1 x 10
4
 cells/cm
2
) and either used directly (subconfluent), or grown 
to 100% confluence + 2 days. Prior to experiments all cells were serum starved in 0.1 % FCS 
for 24 hours. For siRNA was used at a final concentration of 1-10 nMol for 24 hours prior to 
experiments. No specific transfection medium was used as fibroblasts readily absorbed 
siRNA within 24 hours, as confirmed by immuno-blotting. 
Protein extraction, electrophoresis, co-immuno precipitation, and immuno-blotting: 
Cytosolic and nuclear protein fractions were isolated as described earlier and total protein 
concentration was determined by Bradfords‘ method (12, 17). Protein (10 g) were dissolved 
in Laemmli buffer, denatured (95
oC, 5 min), chilled on ice (5 min), centrifuged (13‘000 x g, 
50 sec.), and applied to electrophoresis (4-15% SDS-PAGE). Proteins were transferred onto a 
PVDF membrane by semi-dry electro-transfer, which was confirmed by Ponceaus‘ staining. 
Membranes were washed 3 times with PBS, blocked with 5% skimmed milk in PBS (4
o
C, 
overnight) and incubated with one of the primary antibodies (anti-GR antibody: 0.2 ng/ml, 
sc-1003; p21
(waf1/Cip1)
: 0.2 ng/ml, sc-817; C/EBP-: 0.2 ng/ml, sc-61; p27(Kip): 0.5 ng/ml, sc-
1027). Unbound antibodies were washed off before membranes were incubated with horse 
radish-labeled species specific secondary antibodies for 1 hour at room temperature. After 
washing (3 x 15 min.) with blocking buffer and signals were detected by ECL substrate and 
documented on X-ray film (12, 17). Co-immuno precipitation for GR-C/EBP complexes was 
performed with the same antibodies used for immuno-blotting and followed the protocol 
described earlier (12). 
Electrophoretic mobility shift assay (EMSA): EMSA was performed using a [
32
P]-labelled 
GRE oligo-nucleotide (sc-2545) as described earlier (22, 26). Specificity of the GRE-protein 
complex was characterised by pre-incubating protein extracts with 50 fold excess of 
unlabeled GRE.  
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Immunochemistry and confocal microscopy: Fibroblasts were grown on cover slips (VWR 
International AG, Switzerland) treated and then fixed in methanol/acetic acid (3:1 vol:vol, 15 
min., room temperature). Blocking (PBS, 5% donkey serum, 0.3% Triton-X-100, overnight, 
room temperature). For immuno-fluorescence slides were incubated with a primary Cy3-
labelled goat anti rabbit-IgG antibody (blocking buffer, 1 hour, 4°C), followed by two 
washes with PBS and once with distilled water (5 min), then embedded in Fluorsave
®
. 
Images taken by a Zeiss LSM510 confocal microscope (Carl Zeiss AG, Jena, Germany) and 
analyzed using ImageJ v. 1.33.              
Reverse transcriptase–polymerase chain reaction (RT-PCR): RNeasy® Mini kit (Qiagen, 
Basel, Switzerland) was used to extract total RNA which (1 μg) was transcribed into cDNA 
using murine leukemia virus reverse transcriptase (37°C, 60 min.) (Promega, Madison, US). 
PCR was performed for GR: forward 5‘-CACCCTCACTGGCTGTCGCTTCTC-3‘, reverse  
5‘-TGACAAACGAAAGAGGAG ACCGCC-3‘, 23 cycles: denaturation: (98°C, 20 sec), 
annealing (58°C, 22 sec) and extension (72°C, 30 sec); p21 (primer set, R&D Systems Inc, 
Minneaplois, USA), 30 cycles: denaturation: (94°C, 45 sec), annealing (55°C, 45 sec) and 
extension (72°C, 45 sec);  
2-microglobulin (2-M): forward 5‘-CTCGCGCTACTCTCTCTCTTTCT-3‘, reverse 5‘-
TTAAGTGGGATCGAGACATGTAAGC-3‘, 23 cycles: denaturation (98°C, 30 sec), 
annealing (60°C, 60 sec) and extension (72°C, 60 sec). PCR products were size fractionated 
by electrophoresis in a 1 % agarose gel and products were visualized by ethidium bromide 
(12, 17). 
Active and inactive GR by ELISA:  GR GRE binding was assessed using an ELISA kit 
(Orgenium, Finland) distinguishing total from active GR as described by the distributor. GR 
activation was determined in the same protein extracts used for EMSA and immuno-blotting  
Statistics: Results of protein activation kinetics were compared by paired ANOVA. The 
effect of signal protein inhibitors and siRNAs were compared by paired two-tailed student‘s 
t-test. The null-hypothesis was equality of response between groups. Results were considered 
to be significantly different when the probability (p) was < 0.05. 
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2.2.4 RESULTS 
Cell density and serum modifies the cell compartmental distribution of the GR 
Cell compartmental distribution of the GR was determined by three independent 
methods, confocal microscopy, immuno-blotting, and GRE-ELSIA. Serum (10%) did not 
significantly increase the cell compartment specific expression of the GR in sub-confluent 
fibroblasts within 24 hours, and the GR was located in the cytosol in a peri-nuclear location 
(Fig. 1A).  
In contrast, in confluent serum starved cells the GR could be detected in the cytosol and 
the nucleus and was homogenously distributed and was significantly up-regulated by serum 
(10%) in both cell compartments as early as 3 hours (Fig. 1A). The serum stimulated increase 
of GR protein expression in confluent fibroblasts was preceded by de novo mRNA synthesis 
(Fig. 1B). Only in confluent cells the GR mRNA signal began to increase significantly at 0.5 
hours peaking at 3 hours and declining thereafter (Fig. 1B). GR mRNA signals were 
suppressed by actinomycin D (10 M), but not cycloheximide (10 M) confirming mRNA de 
novo synthesis rather than accumulation (data not shown). 
 
Activation of the GR by steroids is prolonged in sub-confluent cells 
When sub-confluent fibroblasts were treated with dexamethasone (10
-8
 to 10
-6
 M) the GR was 
dose-dependently activated and translocated completely into the nucleus within 3 hours 
(immuno-blotting analysis). The level of the nuclear GR increased significantly within 0.5 
hours compared to start levels (p < 0.001) and remained at a high level over 24 hours with no 
significant difference of the kinetic comparing serum starved cells to those serum (10%) 
stimulated cells (Fig.2A). In confluent fibroblasts the translocation of the GR into the nucleus 
was slower compared to sub-confluent cells, peaked at 1 hour, and declined thereafter to basal 
levels within 24 hours (Fig. 2A). Similar results were obtained using confocal microscopy and 
immuno-blotting. The functional activation of the nuclear GR was confirmed by GRE specific 
EMSA and ELISA, both methods showed that the increase of the GR in the nucleus was 
paralleled by binding of the GR to a synthetic GRE oligo-nucleotide and it confirmed the 
decline of GR activity in the presence of serum within 24 hour (Fig. 2B). 
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Figure 1. (A) In the left three representative confocal images we shown the compartment localisation of the 
GR (green) in the presence and absence of serum (FCS). The nucleus is counterstained with Hoechst dye (blue), 
and densitometric analysis of immuno-blots of the GR in cytosolic and nuclear protein extracts of sub-confluent 
fibroblasts. In the three right panels we display representative confocal images of the cell compartment 
localisation of the GR and densitometric analysis of immuno-blots of the GR in cytosolic and nuclear protein 
extracts of confluent fibroblasts in the presence and absence of serum (FCS). (B) The effect of serum stimulation 
on GR mRNA expression. All above presented data points represent the mean ± S.E.M. of triplicate 
measurements in six different primary fibroblast cell lines. 
 
 Cell density affects serum-dependent C/EBP expression and GR complex formation  
Lung fibroblasts expressed two of the four known C/EBP- isoforms, a 42-45 kDa and a 
30 kDa protein (Fig. 3A). In serum deprived cells the majority of both C/EBP- .isoforms 
was located in the cytosol and independent of cell density. Interestingly in sub-confluent cells 
serum induced a fast increase of the 30 kDa C/EBP- isoform within 3 hours, while the larger 
isoform was not significantly up-regulated before 18 hours (Fig. 3A, upper panel). In contrast, 
in confluent fibroblasts serum C/EBP- was expressed at a much lower level and serum 
induced a significant increase of the large kDa C/EBP- isoform at 6 hours declining nearly 
to basal level within 24 hours (Fig. 3A, lower panel). The 30 kDa isoform was up-regulated at 
18 hours and declined also at 24 hours (Fig.3A, lower panel).  
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Figure 2. (A) The effect of dexamethasone on the cell compartmental localisation of the GR in sub-Confluent 
and confluent fibroblasts and its modification by serum (FCS). Data points represent the mean ± S.E.M. of 
triplicate measurements in six different primary fibroblast cell lines. (B) A representative EMSA of the GR/GRE 
complex in confluent fibroblasts and its activation by serum and dexamethasone. Similar results were obtained 
in three different primary fibroblast lines. 
 
In serum stimulated sub-confluent fibroblasts dexamethason (10
-8
 M) shifted the large 
C/EBP- into the nucleus and the total amount of C/EBP- was lower at 24 hours compared 
to start level (Fig.3B). The cell compartmental distribution of the 30 kDa isoform was not 
shifted by dexamethasone, but its expression was reduced in both compartments (Fig. 3B). 
In addition we characterised the expression pattern of C/EBP- and detected three isoproteins 
at 45, 40 and 30 kDa with a major band at 45 kDa in the cytoplasma of serum treated sub-
confluent and confluent fibroblasts (Fig. 3C). The expression level of all three isoform 
increased when stimulated with serum and reached peak at 6 hours slowly declining 
thereafter. The expression of all three C/EBP- subproteins was higher in confluent cells (n = 
4) compared to sub-confluent fibroblasts (n = 4), but neither their expression nor their cell 
compartmental distribution was affected by dexamethasone (data not shown).  
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Figure 3. (A) The effect of cell density of the kinetic of the expression pattern of two C/EBP- isoproteins (30, 
42 kDa) in total cell protein extracts of human primary lung fibroblasts, depicted as a representative immuno-
blot. Similar results were obtained in five different fibroblast lines. (B) The dexamethasone induced 
activation/translocation of the two C/EBP- isoproteins from the cytosol into the nucleus, depicted as a 
representative immuno-blot. The ratio of the cytosol / nuclear accumulation of the 42 kDa C/EBP- were 
determined by immuno-blots and is shown as mean ± S.E.M. of triplicate measurements in five different primary 
fibroblast cell lines. (C) Representative immuno-blot of the kinetics of C/EBP- isoprotein expression in total 
cell protein extracts of confluent fibroblasts. Similar results were obtained in three other confluent and four sub-
confluent fibroblast lines. d Representative immuno-blots of C/EBP- and – after the GR was targeted and 
immnuo-precipitated with an anti-GR antibody from nuclear cell protein extracts 12 hours after the addition of 
the drug. Similar results were obtained in three other cell lines. 
 
Using an anti-GR antibody to capture the GR-C/EBP complex followed by immuno-blot 
analysis of the C/EBP-isoproteins in the precipitates indicated that the complex composition 
changed over time. At 6 hours a low amount of the 42 kDa C/EBP- and more of the 40/45 
C/EBP- proteins were co-precipitated with the GR (Fig. 3D). At 24 hours the level of the 42 
kDa C/EBP- was the increased, while that of the two C/EBP- isoproteins was reduced in 
the co-precipitates of the GR (Figure 3D).  
 
Cell density and serum modifies the expression of p21
(Waf1/Cip1)
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The kinetics of the GR and C/EBP- activation overlapped for several hours and should 
therefore up-regulate the expression of p21
(Waf1/Cip1)
. In sub-confluent serum starved 
fibroblasts most of the p21
(Waf1/Cip1)
 was located in the nucleus and serum treatment 
significantly increased its expression within 3 hours (p<0.05) declining afterwards (Fig. 4A). 
In confluent cells serum starved cells we observed no significant changes of p21
(Waf1/Cip1)
 
levels, but serum treatment increased its accumulation in the nucleus within 3 hours 
significantly (p<0.01) and maintained it at a high level until 24 hours (Fig. 4A). When 
fibroblasts were treated with dexamethasone (10
-8
 M) the nuclear accumulation of 
p21
(Waf1/Cip1)
 decreased to 50% of its initial level (p<0.01) 24 hours after the addition of the 
steroid in sub-confluent cells (Fig. 4B). In confluent cells the steroid caused a significant 
increase at 6 hours in 0.1% serum (p<0.01) and decreased to basal levels at 24 hours (Fig. 
4B).  
When stimulated with 10% serum and dexamethasone (10
-8
 M) p21
(Waf1/Cip1)
 accumulation 
increased at 3 hours (p<0.01) and maintained at this level until 24 hours in confluent cells 
(Fig. 4B). The observed increase of p21
(Waf1/Cip1)
 expression by serum or the steroid was 
preceded by de novo synthesis of mRNA (data not shown). Blocking steroid signalling by 
pre-treating the cells for 30 minutes with either the glucocorticoid receptor antagonist RU486 
(10
-6
 – 10-8 M) or for one hour with glucocorticoid response element containing decoy-oligo 
nucleotide sequence (10 M) inhibited the expression of p21(Waf1/Cip1) (Fig. 4C). We further 
show that steroid-induced (10
-6
 – 10-8 M) inhibition of fibroblast proliferation involved the 
action of C/EBP- and p21(Waf1/Cip1), while down-regulation of C/EBP- or control siRNA for 
C/EBP- or p21(Waf1/Cip1) had no significant effect (Fig. 4C).  
 
Cell density and p38 MAP kinase regulate steroid dependent expression of p27
(Kip1)
 
Only in confluent fibroblasts steroid treatment (10
-8
 M) induced the expression of a 
second negative cell cycle regulator, p27
(Kip)
 and this effect was independent of the presence 
of serum (Fig. 5A). RU486 (10
-6
 M) or GRE decoy oligo-nucleotides (10 M) diminished the 
effect of dexamethasone, while siRNA for C/EBP- or C/EBP- (1 M) or decoy for NF-B 
(1 M) had no effect (Fig. 5A). Interestingly siRNA for p38 MAP kinase, but not for Erk1/2 
MAP kinase (1 M) significantly reduced the expression of p27(Kip1) in dexamethasone treated 
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cells (Fig. 5B). Furthermore, in the presence of 10% FCS the expression of p27
(Kip1)
 was up- 
regulated when the Erk1/2 signaling pathway was blocked (Fig. 5B).  
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Figure 4. (A) Kinetic of p21(Waf1/Cip1) expression in nuclear protein extracts of serum deprived and serum 
stimulated fibroblasts. (B) The effect of dexamethasone on the expression of 
(Waf1/Cip1)
 expression and its 
modification by serum (FCS) in nuclear protein extracts. Data points in panels A and B represent the mean ± 
S.E.M. of triplicate measurements in five different primary fibroblast cell lines. (C) A representative immuno-
blot of the effect of signal pathway inhibitors on the expression of p21
(Waf1/Cip1)
 in nuclear protein extracts. 
Similar results were obtained in three other cell lines. (D) The effect of dexamethasone, C/EBP-, - , and 
p21
(Waf1/Cip1)
 on serum (FCS) stimulated fibroblast proliferation at the third day. Data points represent the mean 
± S.E.M. of triplicate measurements in six different primary fibroblast cell lines.  
 
We further assessed the role of p21
(Waf1/Cip1) 
and p27
(Kip)
 on proliferation control in 
confluent contact inhibited cells with and without steroids. As expected cell counts of sub-
confluent fibroblast stimulated with 10% FCS increased significantly within 3 days, and a 
single dose of dexamethasone at day 1 reduced the proliferation dose-dependently (10
-6
, 10
-8
 
M) by maximal 38.2 ± 4.7 % (p<0.001). The inhibition of C/EBP- or p21(Waf1/Cip1) siRNA 
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diminished the anti-proliferative effect of the steroid, while siRNA for C/EBP- or p27(Kip1) 
had no such effect (data not shown). In confluent fibroblasts 10% serum did not significantly 
increase cell numbers within 3 days and treatment with neither dexamethasone (10
-6
 M, 10
-8
 
M), nor p21
(Waf1/Cip1)
, nor C/EBP- siRNA had any significant effect on cell numbers (Fig. 
5C). However, when confluent fibroblasts were treated with siRNA for p27
(Kip)
 the confluent 
cell numbers further increased significantly (p<0.02) over a period of 3 days (Fig. 5C). When 
p21
(Waf1/Cip1)
 was blocked in addition to p27
(Kip)
 the contact inhibition of cell proliferation was 
abolished in the presence and absence of the steroid (Fig. 5C). 
 
2.2.5 DISCUSSION 
The presented data showed that the expression and the cell compartmental distribution of 
the GR and its complex formation with the transcription factors C/EBP- and – are affected 
by cell density and the presence of serum. The steroid-dependent expression p21
(Waf1/Cip1)
 
requires the presence of 42 kDa C/EBP-. Only in confluent fibroblasts the steroid induced 
the expression of p27
(Kip)
 via p38 MAP kinase and a 45/40 kDa C/EBP-. Contact inhibition 
of confluent fibroblasts involved the combined action of p21
(Waf1/Cip1)
 and p27
(Kip)
. 
Lung fibroblasts play a key role in the pathology of several human diseases including 
fibrosis, sarcoidosis, chronic obstructive pulmonary disease (COPD), emphysema and asthma 
(22, 30, 32, 33), and glucocorticoids are the major therapeutic drugs used to control the 
inflammatory and the pro-fibrotic aspects of these diseases (1). However, neither the 
contribution of fibroblasts to the pathology of those diseases is clear, nor the benefit of 
inhaled glucocorticoids on the pro-fibrotic processes has been documented (34). It is widely 
accepted that the pathological remodelling of the fibrotic lung is similar to badly controlled 
wound healing. In this study low cell density and serum to mimic he condition of 
inflammation in which fibroblasts have to fill wounds to reconstitute damaged tissue. We 
assumed that such a condition represents the initial phase of wound repair when high serum 
levels are present while being reduced at later stages. Confluent fibroblasts in low serum 
concentration represented intact undamaged tissue, and the addition of serum mimicked to 
confluent fibroblasts mimicked the condition found in tissue adjacent to a wound.  
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Figure 5. (A) The role of GR, C/EBP- and – signaling on the expression of p27(Kip) in nuclear cell extracts 
12 hours after stimulation in confluent fibroblasts. (B) The role of Erk1/2 MAP kinase and p38 MAP kinase 
signaling on the expression of p27
(Kip)
 in nuclear cell extracts 12 hours after stimulation in confluent fibroblasts. 
(C) The role of the GR, C/EBP-, C/EBP –, p21(Waf1/Cip1) and p27(Kip) on fibroblast proliferation at the third day. 
Data points in panels A, B, and C represent the mean ± S.E.M. of triplicate measurements in at least four 
different primary fibroblast cell lines. (D) Summary of the results presented here and interpretation of the 
function of GR-C/EBP complexes as a consequence of cell density. 
 
Our data suggest that cell density affects the localisation of the GR in fibroblasts and also 
modulates its biological availability. The GR is encoded by a single gene which is regulated 
by three independent promoters producing several GR-isoforms which are further modified by 
post-translational modifications. The expression of the various GR-isoforms is assumed to be 
cell type, tissue, or species specific, while their specific function is not well defined (35, 36). 
The best studied GR-isoforms are GR and GR. It was assumed that the GR isoform is 
only expressed in the nucleus where it competes with the GR-for GRE binding (36, 37). 
However, the expression of GR is species specific and may be cell type specific (34-37). 
Based on its characteristic molecular weight we observed only the GR isoform under all 
conditions, including confluent fibroblasts and glucocorticoid activation in human fibroblasts. 
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However, in confluent fibroblasts the nuclear fraction of the GR was significantly increased 
compared to subconfluent cells. Nevertheless the GRE binding capacity of the nuclear GR 
isolated from confluent cells was not increased compared to subconfluent cells as assessed by 
EMSA and ELISA. Dexamethasone increased the GR – GRE binding capacity under all 
conditions indicating that the nuclear location of the GR in confluent fibroblasts was not 
caused by increased activation. Cell type and cell layer location specific distribution and 
activation of the GR is not new and had been described in the placenta (38). Interestingly, the 
authors observed that extended treatment with glucocorticoids resulted in a 90% down-
regulation of GR expression in placenta fibroblasts, which is comparable with the effect we 
observed in lung fibroblast cultures. In our experiments the consequence of GR depletion was 
the loss of the anti-proliferative effect of the glucocorticoid. 
In this study we provide evidence that the complexes that are formed by the GR and members 
of the C/EBP family is affected by cell density and that the composition of the complex seems 
to regulate the effect of steroids on the cell cycle regulator that is subsequently activated. 
While a GR-C/EBP- complex results in p21(Waf1/Cip1) expression, that of the GR with C/EBP-
 seems to lead to p27(Kip) activation. We further provide evidence that the 30kDa isoproteins 
of both C/EBPs are not significantly binding to the GR. The anti-proliferative effect of 
glucocorticoids is clearly linked with the activation of C/EBP- and p21(Waf1/Cip1) (10, 15-18), 
while the necessity of p53 for p21
(Waf1/Cip1)
 gene expression is not clear (10, 38), and could 
also be a feedback mechanism of p53 on GR expression (31, 39). Interestingly, the nuclear 
localisation of accumulation of p21
(Waf1/Cip1)
 extended the life-span of senescent human 
fibroblasts in the presence of dexamethasone (40) and in long term treated cells of Cushing 
syndrome patients (18). Together with the observation that in pancreatic fibroblasts nuclear 
p21
(Waf1/Cip1)
 was associated with a phenotypic switch of the cells into myo-fibroblasts (29) 
suggests that p21
(Waf1/Cip1)
 in confluent fibroblasts may have different properties compared to 
proliferating sub-confluent cells or may need additional factors to control proliferation.  
In addition to p21
(Waf1/Cip1)
 dexamethasone induced the expression of a second cell cycle 
control protein p27
(Kip)
, which has been reported in other cell types before (41) and may 
depend on residue specific phosphorylation or dimerisation of the GR (42). Again the 
interaction of p21
(Waf1/Cip1) 
with p27
(Kip)
 may be cell type or species specific (3, 15, 37, 43). In 
our experiments deprivation of p21
(Waf1/Cip1)
 expression alone in confluent serum exposed 
fibroblasts was insufficient to overcome contact inhibition. Only when p27
(Kip)
 was also 
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down-regulated confluent serum stimulated fibroblasts lost contact inhibition and grew in 
multiple layers, the effect could not be stopped by dexamethasone treatment. The interaction 
of p27
(Kip)
 with p21
(Waf1/Cip1)
 in regard to cell proliferation control had been described by 
others (15, 37) and may even make cell cycle arrest independent of cyclin dependent kinase 2 
(3, 43).  
In figure 5D we provide a schemata which summarises our findings, which imply that in 
sub-confluent fibroblasts the GR forms a complex with the 42 kDa C/EBP- which leads to 
p21
(Waf1/Cip1)
 expression and cell cycle arrest, while in confluent cells the GR binds preferably 
to the 45/40 kDa C/EBP- isoproteins which induces p27(Kip) expression. This data further 
supports the idea that the function of the GR is modified by cell differentiation and 
inflammation and needs to be further addressed in the context of pathologies that either 
develops steroid resistance or that do not respond well to steroid therapy. 
 
 
ACKNOWLEDGEMENTS:  
This research was s was supported by the Swiss National Foundation (3200B0-105737/1) and 
ASTRA Zeneca, Lund, Sweden. We would like to thank Mr. S‘ng CT for reading and editing 
the manuscript.  
 
 
 
 
 
 
 
 
 
 
 
Specific glucocorticoids receptor C/EBP complexes 
 45 
2.2.6 REFERENCES 
1. Buckingham JC. Glucocorticoids: exemplars of multi-tasking. Br J Pharmacol 
2006;147:S258-S268.  
2. Dostert A, Heinzel T. Negative glucocorticoid receptor response elements and their role in 
glucocorticoid action. Pharm Des 2004;10:2807-2816. 
3. Smith E, Redman RA, Logg CR, Coetzee G.A, Kasahara N, Frenkel B. Glucocorticoids 
inhibit developmental stage-specific osteoblast cell cycle. Dissociation of cyclin A-cyclin-
dependent kinase 2 from E2F4-p130 complexes. J Biol Chem 2000;275:19992-20001. 
4. Wochnik G.M, Ruegg J, Abel G.A, Schmidt U, Holsboer F, Rein T FK506-binding 
proteins 51 and 52 differentially regulate dynein interaction and nuclear translocation of 
the glucocorticoid receptor in mammalian cells. J Biol Chem 2005;280:4609-4616. 
5. Jeffery PK. Remodeling and inflammation of bronchi in asthma and chronic obstructive 
pulmonary disease. Proc Am Thorac Soc 2004;1:176-183. 
6. Silva CM, Powell-Oliver F E, Jewell CM, Sar M, Allgood VE, Cidlowski JA. Regulation 
of the human glucocorticoid receptor by long-term and chronic treatment with 
glucocorticoid. Steroids 1994;59:436-442 
7. Andreae J, Tripmacher R, Weltrich R, Rohde W, Keitzer R, Wahn U, Paul K, Buttgereit F. 
Effect of glucocorticoid therapy on glucocorticoid receptors in children with autoimmune 
diseases. Pediatr Res 2001;49:130-135 
8. Wallace AD, Cidlowski JA. Proteasome-mediated Glucocorticoid Receptor degradation 
restricts transcriptional signaling by glucocorticoids. J Biol Chem 2001;267:42714-42721 
9. Aittomaki S, Pesu M, Groner B, Janne OA, Palvimo J., Silvennoinen O. Cooperation 
among Stat1, glucocorticoid receptor, and PU.1 in transcriptional activation of the high-
affinity Fc gamma receptor I in monocytes. J Immunol 2000;164:5689-5697. 
10. Terada Y, Okado T, Inoshita S, Hanada S, Kuwahara M, Sasaki S, Yamamoto T, Marumo 
F. Glucocorticoids stimulate p21(CIP1) in mesangial cells and in anti-GBM 
glomerulonephritis. Kidney Int 2001;59:1706-1716. 
11. Mukhopadhyay SS, Wyszomierski SL, Gronostajski RM, Rosen JM. Differential 
interactions of specific nuclear factor I isoforms with the glucocorticoid receptor and 
STAT5 in the cooperative regulation of WAP gene transcription. Mol Cell Biol 
2001;21:6859-6869. 
12. Rüdiger JJ, Roth M, Bihl MP, Cornelius BC, Johnso, M, Ziesche R, Block LH. Interaction 
of C/EBPalpha and the glucocorticoid receptor in vivo and in nontransformed human cells. 
FASEB J 2002;16:177-184. 
13. Hayashi R, Wada H, Ito K, Adcock IM. Effects of glucocorticoids on gene transcription. 
Eur J Pharmacol 2004;500:51-62. 
Specific glucocorticoids receptor C/EBP complexes 
 46 
14. Ki SH, Cho IJ, Choi DW, Kim SG. Glucocorticoid receptor (GR)-associated SMRT 
binding to C/EBPbeta TAD and Nrf2 Neh4/5: role of SMRT recruited to GR in GSTA2 
gene repression. Mol Cell Biol 2005;25:4150-4165. 
15. Ramalingam A, Hirai A,. Thompson EA. Glucocorticoid inhibition of fibroblast 
proliferation and regulation of the cyclin kinase inhibitor p21Cip1. Mol Endocrino 1997; 
11:577-586. 
16. Cram EJ, Ramos RA, Wang EC, Cha HH, Nishio Y, Firestone G.L. Role of the 
CCAAT/enhancer binding protein-alpha transcription factor in the glucocorticoid 
stimulation of p21waf1/cip1 gene promoter activity in growth-arrested rat hepatoma cells. 
J Biol Chem 1998; 273:2008-2014. 
17. Eickelberg O, Roth M, Lorx R, Bruce V, Rudiger J, Johnson M, Block LH. Ligand- 
independent activation of the glucocorticoid receptor by beta2-adrenergic receptor agonists 
in primary human lung fibroblasts and vascular smooth muscle cells. J Biol Chem 1999; 
274:1005-1010. 
18. Oddera S, Cagnoni F, Mangraviti S, Giron-Michel J, Popova O, Canonica G.W. Effects of 
triamcinolone acetonide on adult human lung fibroblasts: decrease in proliferation, surface 
molecule expression and mediator release. Int Arch Allergy. Immunol 2002; 129:152-159. 
19. Dube J, Chakir J, Laviolette M, Saint Martin S, Boutet M, Desrochers C, Auger F, Boulet 
LP. In vitro procollagen synthesis and proliferative phenotype of bronchial fibroblasts 
from normal and asthmatic subjects. Lab Invest 1998;78:297-307 
20. Warshamana G.S, Martinez S, Lasky JA, Corti M, Brody AR. Dexamethasone activates 
expression of the PDGF-alpha receptor and induces lung fibroblast proliferation. Am J 
Physiol 1998;274:L499-L507. 
21. Dik WA, Versnel MA, Naber BA, Janssen DJ, van Kaam AH, Zimmermann LJ. 
Dexamethasone treatment does not inhibit fibroproliferation in chronic lung disease of 
prematurity. Eur Respir J 2003;21:842-847 
22. Roth M, Johnson PR, Borger P, Bihl MP, Rüdiger JJ, King G.G., Ge Q, Hostettler K, 
Burgess JK, Black JL, Tamm M. Dysfunctional interaction of C/EBPalpha and the 
glucocorticoid receptor in asthmatic bronchial smooth-muscle cells. N Engl J Med 2004; 
351:560-574. 
23. Woodruff PG., Dolganov G.M, Ferrando RE, Donnelly S, Hays SR, Solberg OD, Carter R, 
Wong HH, Cadbury PS, Fahy JV. Hyperplasia of smooth muscle in mild to moderate 
asthma without changes in cell size or gene expression. Am J Respir Crit Care Med 2004; 
169:1001-1006.  
24. Borger P, Matsumoto H, Boustany S, Cornelsen-Gencay MM, Tamm M, Burgess JK, King 
GG, Black JL, Roth M. Differential expression and drug dependent regulation of CCAAT/ 
Enhancer Binding Proteins (C/EBP) in airway smooth muscle cells of asthma and COPD 
patients. J Allergy Clin Immunol 2007; 119:98-105.  
25. Salvato G.. Quantitative and morphological analysis of the vascular bed in bronchial 
biopsy specimens from asthmatic and non-asthmatic subjects. Thorax 2001; 56:902-906. 
Specific glucocorticoids receptor C/EBP complexes 
 47 
26. Goulet S, Bihl MP, Gambazzi F, Tamm M, Roth M. Opposite effect of corticosteroids and 
long-acting beta(2)-agonists on serum- and TGF-beta(1)-induced extracellular matrix 
deposition by primary human lung fibroblasts. J Cell Physiol 2006; 210:167-176. 
27. Promwikorn W, Hawley SR, Pennington SR. Changes in p21 (Cip1) and p27(Kip1) 
expression are not required for cell cycle entry and progression to S phase in Swiss 3T3 
cells. Cell Signal 2000; 12:619-627.  
28. Cariveau MJ, Kovacs CJ, Allison RR, Johnke RM, Kalmus G.W, Evans M. The 
expression of p21/WAF-1 and cyclin B1 mediate mitotic delay in x-irradiated fibroblasts. 
Anticancer Res 2005;25:1123-9112 
29. Manapov F, Muller P, Rychly J. Translocation of p21(Cip1/WAF1) from the nucleus to 
the cytoplasm correlates with pancreatic myofibroblast to fibroblast cell conversion. Gut 
2005;54:814-822. 
30. Hausman G.J. The influence of dexamethasone and insulin on expression of 
CCAAT/enhancer binding protein isoforms during preadipocyte differentiation in porcine 
stromal-vascular cell cultures: evidence for very early expression of C/EBPalpha. J Anim 
Sci 2000;78:1227-1235. 
31. Zhu XY, Liu YJ, Lu J, Xu RB. Knockdown of glucocorticoid receptor expression by RNA 
interference promotes cell proliferation in murine macrophage RAW264.7 cells. J Steroid 
Biochem Mol Biol 2004;92:375-382. 
32. Noordhoek JA, Postma DS, Chong LL, Vos JT, Kauffman HF, Timens W, van Straaten 
JF. Different proliferative capacity of lung fibroblasts obtained from control subjects and 
patients with emphysema. Exp Lung Res 2003;29:291-302. 
33. Garantziotis S, Steele MP, Schwartz DA. Pulmonary fibrosis: thinking outside of the lung. 
J Clin Invest 2004;114:319-321. 
34. Barnes PJ, Hansel TT. Prospects for new drugs for chronic obstructive pulmonary disease. 
Lancet 2004;364:985-996. 
35. Yudt MR, Cidlowski JA. The glucocorticoid receptor: coding a diversity of proteins and 
responses through a single gene. Mol Endocrinol 2002;16:1719-1726. 
36. Bodwell JE, Webster JC, Jewell C M, Cidlowksi JA, Hu JM, Munck A. Glucocorticoid 
receptor phosphorylation: overview, function and cell cycle-dependence. J Steroid 
Biochem Mol Biol 1998;65:91-99.  
37. Oakley RH, Jewell CM, Yudt MR, Bofetiado DM, Cidlowksi JA. The dominant negative 
activity of the human glucocorticoid receptor beta isoform. Specificity and mechanisms of 
action. J Biol Chem 1999; 274:27857-27866. 
38. Lee MJ, Wang Z, Yee H, Ma Y, Swenson N, Yang L, Kadner SS, Baergen RN, Logan SK, 
Garabedian MJ, Guller S. Expression and regulation of glucocorticoid receptor in human 
placental villous fibroblasts. Endocrinol 2005; 146:4619-4626. 
Specific glucocorticoids receptor C/EBP complexes 
 48 
39. Urban G., Golden T, Aragon IV, Cowsert L, Cooper SR, Dean NM, Honkanen RE. 
Identification of a functional link for the p53 tumor suppressor protein in dexamethasone-
induced growth suppression. J Biol Chem 2003;278:9747-9753.  
40. Mawal-Dewan M, Frisoni L, Cristofalo VJ, Sell C. Extension of replicative lifespan in WI-
38 human fibroblasts by dexamethasone treatment is accompanied by suppression of p21 
Waf1/Cip1/Sdi1 levels. Exp Cell Res 2003;285:91-98. 
41. Wang Z, Garabedian MJ. Modulation of glucocorticoid receptor transcriptional activation, 
phosphorylation, and growth inhibition by p27Kip1. J Biol Chem 2003;278:50897-50901. 
42. Rogatsky I, Hittelman AB, Pearce D, Garabedian MJ. Distinct glucocorticoid receptor 
transcriptional regulatory surfaces mediate the cytotoxic and cytostatic effects of 
glucocorticoids. Mol Cell Biol 1999; 19:5036-5049. 
43. Reichert M, Eick D. Analysis of cell cycle arrest in adipocyte differentiation. 
Oncogene1999;18:459-466.  
 Introduction 
 
CHAPTER 3 
Tachyphylaxis and the prolonged inhibitory effect of 
mometasone on lung tissue remodelling 
 
Glucocorticoids are very effective in asthma treatment, but in long-term usage they cause 
severe side effects and can result in reduced expression and function of the GR assigned as 
tachyphylaxis. This in turn leads to reduce steroid response. 
Mometasone has recently been introduced to asthma treatment. Compared to other 
steroids it is chracterised by a long lasting action at low doses and less frequent application. 
Like other steroids, it penetrates the cell membrane passively, binds to the GR, followed by 
translocation into the nucleus where it acts as a transcription factor. However as other steroids 
the mometasone activated GR can also interact with other transcription factors, such as AP-1 
and NF-B to expand its functions. The mechanisms of the action of mometasone are not 
fully understood yet. 
Lung mesenchymal cell activation and proliferation importantly contribute to the 
pathogenesis of inflammatory lung diseases, here we used 5% fetal calf serum (FCS) in  
fibroblasts and smooth muscle cells to mimic inflammation. 
 
3.1 OBJECTIVES:  
In this study I compared the effect of the classical glucocorticoid, dexametasone to that of 
the long acting glucocorticoid mometasone on: 
1. the effect of mometasone on the expression and activation of the GR,  
2. the effect of mometasone on the expression and activation of C/EBP-α,  
3. the effect of mometasone on the expression and activation of p21(Waf1/Cip1),  
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4. the effect of mometasone on the expression and activation of matrix 
metalloproteinases,  
5. the effect of mometasone on extracellular matrix deposition,  
6. the anti-proliferative capacity of mometasone on serum activated primary human lung 
fibroblasts and smooth muscle cells.  
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At a Glance Commentary: In this study we found that mometasone was a more potent 
inhibitor of cell proliferation and keeps the glucocorticoids receptor for a prolonged period 
activated. Potentially these differences are caused by reduced or absent tachyphylaxis of the 
glucocorticoid receptor after treatment with mometasone. Our findings might be relevant for 
therapy of inflammatory lung diseases with high dose or repeated steroids. 
 
3.2.1 Abstract 
Rationale: The long term steroid therapy can be impaired by reduced expression and function 
of the glucocorticoid receptor, tachyphylaxis. Objectives: In this study we compared the 
effect of dexamethasone to long acting mometasone on the expression and activation of the 
glucocorticoid receptor, C/EBP- p21(Waf1/Cip1), matrix metalloproteinase, extracellular matrix 
deposition,
 
and their anti-proliferative capacity in primary human lung fibroblasts and smooth 
muscle cells. Measurements and Main Results: Protein expression was determined by 
immuno-blotting and gelatine zymography, proliferation by thymidine incorporation. 
Dexamethasone induced glucocorticoid receptor activity decreased significantly faster at 6 
hours compared to that induced by mometasone at 24 hours. Similarly drug specific effects 
were observed for the expression of C/EBP- and p21(Waf1/Cip1). The anti-proliferative effect 
of mometasone was significantly stronger, long lasting, and could not be washed out 
compared to dexamethasone. Furthermore, when treated with mometasone a second dose on 
day two further reduced fibroblast proliferation, while dexamethasone had no such effect. 
Similar anti-proliferative effects were observed in bronchial and vascular smooth muscle 
cells. Regarding airway remodelling we observed that mometasone, in contrast to other 
steroids, did further stimulate serum dependent synthesis and deposition of extracellular 
matrix and did not affected matrix metalloproteinase-2 and -9 expressions or activity. 
Conclusions: Our findings indicate that mometasone does not induce tachyphylaxis and has a 
preferable effect on airway remodelling. Therefore mometasone might help to reduce steroid 
dosage in asthma therapy and thereby reduce the risk of tachyphylaxis and tissue remodelling.  
(Words: 237) 
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3.2.2 Introduction 
Airway remodelling is a pathology shared by most chronic inflammatory lung diseases 
(1-4). Tissue repair processes of the airway wall‘s sub-mucosa include increased extracellular 
matrix deposition and increased numbers of (myo-) fibroblasts and smooth muscle cells 
altering lung function (2, 4). 
Novel long lasting steroids such as mometasone have been introduced to asthma therapy 
to reduce steroid dosage and application frequency (5). Mometasone has a prolonged 
bioavailability in the lung (6, 7), and its long term systemic effect on cortisol reduction is 
lower than other steroids (8, 9). All steroids penetrate the cell membrane passively, bind to the 
glucocorticoid receptor (GR), which then migrates into the nucleus to act as a transcription 
factor (10, 11). Steroids, including mometasone, inhibit other transcription factors, AP-1 and 
NF-B (12) which is substrates for proliferative signal transducers (13). This action might 
also inhibit the AP-1 dependent histone acetylation that is necessary for gene transcription 
(14), and may explain partly mometasone‘s anti-proliferative effect. Furthermore, 
mometasone activates the CREB binding protein, a histone acetylase, and controls DNA 
methylation in NF-B activated genes (15).  
The deregulation of fibroblast and bronchial smooth muscle cell function in the airway 
sub-mucosa may be a cause for lasting structural changes in chronic inflammatory lung 
diseases which increase long-term morbidity (2, 16 - 18). However, it is unclear whether 
infiltrating activated immune cells stimulate the fibrotic process, or if their infiltration follows 
the release of cytokines by lung resident cells. Therefore lung mesenchymal cell activation 
and proliferation importantly contributes to the pathogenesis of inflammatory lung diseases, 
but is often neglected as a therapeutic aim.  
Steroids in general have a potent anti-proliferative effect (10, 19), but for mometasone the 
information is limited (20). Airway wall stiffness and flexibility correlates with the 
accumulation of extracellular matrix (ECM), and may be increased by classical steroids in 
inflamed tissue and a beneficial effect of steroids on airway wall remodelling would not occur 
in the inflamed lung (21). Furthermore, in fibroblasts steroids down-regulate GR expression 
within hours which might result in a decreased response to the drugs in long-term, 
tachypylaxis (22-24). Steroid response can also be lost by proteasomal GR protein 
degradation (25) or by suppression of de novo synthesis at the transcriptional level (26), such 
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effects are most probably independent of the steroid‘s glucocorticoid receptor-binding affinity 
and may be drug specific. 
The aim of this study was to compare the anti proliferative effect and the underlying 
molecular mechanism a short acting steroids to that a long-acting steroid in primary human 
lung mesenchymal cells of non-asthmatic adults. We also compared the effect of classical 
steroids to mometasone on ECM deposition and used 5% serum to mimic inflammation (21). 
 
3.2.3 Materials and Methods 
Cell culture and experimental conditions: Human lung fibroblast, pulmonary 
vascular and bronchial smooth muscle cells were isolated and grown as described earlier (27-
29). Experiments were performed between 3
rd
 to 7
th
 cell passages. Prior to treatment cells 
(10
4
/cm
2
) were serum deprived (0.1% FCS) for 24 or 36 hrs. RU486 or steroids were added 
30 min prior to other treatments. 
Cell proliferation: Serum deprived cells were stimulated (5% FCS) and [
3
H]-thymidine 
incorporation was determined during the last 8 hrs and quantified by liquid scintillation 
counting (19). 
Immuno-histochemistry: Cells grown on cover slips were washed 3x with phosphate 
buffered saline (PBS) and fixated with methanol: acidic acid (3:1). Slides were washed twice 
before endogenous peroxidase was inhibited (0.1% NaN3, 0.3% H2O2), washed twice and 
unspecific antibody binding was blocked (5% FCS, 0.05% Tween-20 in PBS; 1 hr). Slides 
were incubated overnight with 1:400 diluted GR antibodies (sc-1003, Santa Cruz 
Biotechnology, CA) in blocking buffer (4°C), washed twice and incubated with horseradish 
peroxidase-labelled antibodies (sc-2004, 1:1000, blocking buffer, 1 hr). Slides were washed 
3x with PBS and stained using an AEC Chromogen Kit (AEC101, Sigma, Saint Louis, MO). 
Images were documented by Analysis-D soft imaging system (Olympus IX50 microscope, 
objective 40x). The same procedure was performed with 1:300 diluted p21
(Waf1/Cip1) 
antibodies 
(610234, BD Biosciences PharmingenSan Diego, CA) and 1:1000 diluted horseradish 
peroxidase-labelled antibodies (sc-2005). 
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Nuclear and cytosolic extracts and immuno-blotting: Cytosolic and nuclear proteins were 
prepared and the protein-concentration was determined by Bradford's method as described 
earlier (19). Total protein (10 µg) was size-fractionated in a denaturing 4-15% SDS-PAGE 
and transferred onto PVDF membranes (Millipore Corp., MA); controlled by Ponceau's 
staining (19). Membranes were incubated in blocking buffer (10mM Tris, 150mM NaCl, 
0.05% Tween-20, 5% skimmed milk) for 1 hr, followed by overnight incubation (4°C) with 
either glucocorticoid receptor, C/EBP-, or p21(Waf1/Cip1) specific antibodies (sc-8992, sc-61, 
sc-6246; Santa Cruz Biotech). Unbound antibodies were washed off and membranes were 
incubated (30 min) with horseradish peroxidase-labelled species specific antibodies 
(Chemicon). Protein bands were detected by ECL (Pierce, IL) for evaluation of optical density 
(19). 
Extracellular matrix synthesis and gelatinase activity: Deposition of extracellular matrix 
was determined by [
3
H]-proline incorporation (21) and gelatinases MMP-2 and -9 were 
detected by gelatine zymography (30). 
Reverse transcriptase–polymerase chain reaction (RT-PCR): Total RNA was extracted 
using RNeasy
®
 Mini kit (Qiagen, Basel, Switzerland) and 1 g was transcribed into cDNA 
using murine leukemia virus reverse transcriptase (Promega, Madison, WI). PCR primers 
used were: GR forward 5‘-CACCCTCACTGGCTGTCGCTTCTC-3‘, reverse 5‘-TGA 
CAAACGAAAGAGGAGACCGCC-3‘, 23 cycles: denaturation: (98°C, 20 sec), annealing 
(58°C, 22 sec), extension (72°C, 30 sec); p21 (primer set, R&D Systems Inc, MI); 2-
microglobulin (2-M): forward 5‘-CTCGCGCTACTCTCTCTCTTTCT-3‘, reverse 5‘-
TTAAGTGGGATCGAGACATGTAAGC-3‘, 23 cycles: denaturation (98°C, 30 sec), 
annealing (60°C, 60 sec), extension (72°C, 60 sec). PCR products were analysed by 
electrophoresis (1% agarose gel) stained with ethidium bromide (21). 
Statistics: Statistics were performed using SPSS 11.5.1. (SPSS Inc., Chicago, IL). Student‘s 
t-test was used for densitometric data and ANOVA for proliferation, with p<0.05 indicting 
significance from H0-hypothesis of equal distribution.  
Additional details for all methods are provided in data supplement 
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3.2.4 Results 
Dexamethasone, budesonide, and fluticasone had a similar dose-dependent anti-
proliferative effect and inhibited serum-induced (5% FCS, 24 hrs) [
3
H]-thymidine 
incorporation significantly (p<0.05) at concentrations > 10
-7
 M with no significant difference 
comparing the drugs to each other (figure 1A). Compared to dexamethasone mometasone 
significantly decreased fibroblast proliferation at a lower a concentration > 10
-10
 M (p<0.05; 
figure 1A). The anti-proliferative effects of all four steroids was blocked by 30 min pre-
incubation of fibroblasts with 10
-6
 M RU486 (figure 1A). Assessing the anti-proliferative 
effect of the four steroids in two other lung cell types we observed similar drug specific 
effects in bronchial smooth muscle cells (figure 1B) and pulmonary vascular smooth muscle 
cells (figure 1C). As in fibroblasts the occupation of the GR by RU486 inhibited the anti-
proliferative effect of all steroids (figure 1B, 1C). Since we observed no significant anti-
proliferative differences comparing budesonide or fluticasone to dexamethasone we 
performed all subsequent experiments comparing dexamethasone to mometasone in lung 
fibroblasts. 
Kinetic of GR trafficking and glucocorticoid specific down-regulation. GR activity was 
determined by immuno-blotting and immuno-histochemistry. In serum-starved cells and in 
cells treated with 5% FCS the GR was located in a restricted cytosolic closed to the nuclear 
membrane (figure 2A). One hour after addition of a steroid (10
-8
 M) a significant amount of 
the GR was shifted into the nucleus. Based on densitometric analysis we observed no 
significant differences comparing the effect of dexamethasone (557±16 optical units: OU) to 
mometasone (503±34 OU), however compared to 5% FCS (397±36 OU) the effect of both 
steroids was significant with a p<0.01 (figure 2B). Furthermore, six hours after the addition of 
dexamethasone the expression of the GR in the nucleus (288±19 OU) was significantly 
reduced (p<0.01) compared to mometasone (475±30 OU). When the incubation of fibroblasts 
with steroids was extended to 24 hrs dexamethasone treated cells showed a further down-
regulation of GR expression (254±23 OU), while this effect in the presence of mometasone 
(425±18 OU) was significantly lower (p<0.01) (figure 2B). We also could confirm that 
dexamethasone treatment was followed by proteosomal degradation of the GR as the steroid 
dependent down-regulation of GR expression was inhibited when the cells were pre-treated 
with the 26 S proteasome inhibitor MG-132 (figure 2A). 
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Immuno-blotting of nuclear protein extracts confirmed the drug specific kinetic of GR 
activation and down-regulation (figure 2C). A summary of the densitometric analysis of the  
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Figure 1:  (A) Dose-dependent inhibition of serum-stimulated lung fibroblast proliferation by different steroids. 
To determine proliferation fibroblasts (10
6
/cm
2
) were serum starved for 24 hours (0.1% FCS) before 
proliferation was stimulated by 5% FCS. The drugs were added together with the growth medium (5% FCS 
containing RPMI 1640) and were  present over the entire test period. To determine the involvement of the GR in 
the anti-proliferative effect of steroid cells were pre-incubated for 30 minutes with 10
-6
 M RU486, prior to the 
addition of one of the steroids. (B) Similar experiments were performed in primary human bronchial smooth 
muscle cells and (C) in pulmonary vascular smooth muscle cells. Bars represent the mean ± S.E.M. calculated 
for the indicate number of cell lines. Experiments were performed at least in duplicate in each cell line. For all 
graphs statistically significant differences (paired, two-tailed student’s t-test) of steroid compared to 5% FCS 
stimulated cells are indicated by: *: p< 0.05; **: p < 0.01. 
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accumulation of GR in the nucleus in five different human lung fibroblast cell lines is shown 
in figure 2D. Both steroids caused a fast increase in nuclear GR accumulation within 1 and 3 
hrs and a subsequent significant decline of the GR signal at six hours in the presence of 
dexamethasone (57±17% vs. control, p<0.05), but not with mometasone (132±16% vs. 
control). 
In addition we analysed the effect of the two steroids on the expression of total GR. 
When fibroblasts were cultivated in the presence of a steroid for 16 hrs the overall expression 
of the GR was significantly lower compared to control cells in the presence of 5% FCS and, 
this decrease is more pronounced in the presence of dexamethasone (10
-8
 M) compared to 
mometasone (10
-8
 M) (figure 2E). We did not observe a significant effect of any treatment on 
the ratio of the GR- to GR- (figure 2E). Furthermore, we could confirm that the 
proteasome inhibitor MG-132 significantly inhibited the steroid dependent degradation of the 
GR (figure 2E). 
 In addition we determined the effect of the two steroids on the mRNA transcription of 
the GR. The expression level of the mRNA encoding for various genes of interest was 
determined by RT-PCR as a ratio to -actin mRNA expression. Cells that were kept in 
starving medium (0.1% FCS) were used as control for each time point. Stimulation of 
fibroblasts with 5% FCS-induced an increase expression of the GR mRNA significantly at all 
time points after 3 hrs, and both steroids significantly down regulated this effect until 24 hrs. 
However, in the presence of mometasone GR mRNA levels dropped less compared to 
dexamethasone and at 6 hrs started to incline again reaching approximately 50% of the 5% 
FCS induced level (figure 3A). The inhibitory effect of the two steroids on the GR mRNA 
was not observed when the cells had been pre-treated with RU486 (10
-6
 M) for 30 min (data 
not shown). 
To further elucidate the signaling pathway that mediates the anti-proliferative action of 
the two steroids we compared the effect of the two steroids on the transcription of C/EBP- 
and p21
(Waf1/Cip1)
 in human lung fibroblasts and airway smooth muscle cells. In figure 3B we 
show that 5% FCS induced an increase of the transcription of C/EBP- within 3 hrs and 
declined after 3 hrs; this effect was not significantly altered by the steroids, even so 
mometasone seemed to extend the active period for 6 hrs. In the same samples we examined 
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the expression of the mRNA encoding for p21
(Waf1/Cip1)
 which was not stimulated by 5% FCS, 
but in the presence of any of the two steroids at 6 and 24 hrs. Mometasone induced a stronger 
signal of p21
(Waf1/Cip1)
 at all time points compared to dexamethasone (figure 3C). 
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Figure 2. (A) Representative photographs of the cell compartmental distribution of the GR in 5% FCS stimulated 
fibroblasts (upper panel row), or in cells treated with 10
-8
 M dexamethasone (middle row) or 10
-8
 M 
mometasone (lower row). The effect of the proteasome inhibitor MG-132 (10
-6
 M) on dexamethasone stimulated 
GR depletion is at 24 hours (middle row, last picture).  Unspecific staining due to the 2
nd
 antibody is presented 
at the end of the mometasone treatment. (B) Time course of the nuclear accumulation of the GR determined by 
densitometrical analysis of confocal microscopy (100 cells were analysed for each set) in 5% FCS treated 
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control fibroblasts versus treatment with dexamethasone  (10
-8
M) or mometasone (10
-8
 M). Each data point 
represents the mean ± S.E.M. calculated for 5 independent fibroblast cell lines. * indicates a statistic significant 
difference with p < 0.05 comparing the effect of dexamethasone (10
-8
 M) or mometasone (10
-8
 M) to 5% FCS by 
paired, two tailed student’s t-test. (C) Representative Immuno-blot of GR accumulation in the nuclear protein 
fraction of fibroblasts and its stimulation by dexamethasone (dex) or mometasone (mom) at a concentration of 
10
-8
 M. Similar results were obtained in four additional fibroblast lines. (D) Semi-quantitative analysis of the 
kinetic of steroid induced nuclear GR accumulation relative to un-treated cells. Each data point represents the 
mean ± S.E.M. of five fibroblast lines. * indicates a statistic significant difference with p < 0.05 comparing the 
effect of dexamethasone (10
-8
 M) or mometasone (10
-8
 M) to 5% FCS by paired, two tailed student’s t-test. (E) 
The effect of dexamethasone (dex) and mometasone (mom) on the expression of total GR and isoforms in human 
lung fibroblasts. Similar results were obtained in four other lines. 
 
The function of C/EBP- and p21(Waf1/Cip1) depends on their cell compartmentalisation, 
therefore we assessed the localisation of both proteins before cells were treated with any 
steroid and 24 hrs later. In figure 3D we show representative immuno-histochemical staining 
for both factors under different culture conditions. In resting cells we observed no C/EBP-, 
while 24 hrs in 5% FCS increased the signal in the cytosol, and it was shifted into the nucleus 
when treated with one of the steroids (10
-8
 M) (figure 3D).  
Compared to 0.1% FCS treatment 5% FCS for 24 and 48 hrs did not induce any increase 
of p21
(Waf1/Cip1)
 protein expression, which was expressed at a similar level in the cytosol as 
well as in the nucleus (figure 3D). Stimulation with dexamethasone or mometasone (10
-8
 M) 
induced a significant increase of total p21
(Waf1/Cip1)
 and also in the nucleus within 24 hrs 
(figure 3D). Nuclear accumulation of p21
(Waf1/Cip1)
 was maintained for 48 hrs when fibroblasts 
were treated with mometasone, while cells treated with dexamethasone expressed 
p21
(Waf1/Cip1)
 levels that were similar to 5% FCS alone (figure 3D). 
To determine the duration of the anti-proliferative effect after a single dose of a steroid, 
fibroblasts were treated with one of the steroids (10
-7
 M) for 24 hrs. The cells were than 
washed twice with PBS and normal growth medium was added for an additional 24 hrs. As 
depicted in figure 4A fibroblasts that had been treated with mometasone proliferated 
significantly slower compared to cells treated with dexamethasone. RU486 (10
-6
 M) 
counteracted the anti-proliferative effect of mometasone and dexamethasone (figure 4A). 
Since dexamethasone and mometasone had different effects on the GR expression and mRNA 
synthesis at 24 hrs we investigated if the anti-proliferative effect of either steroid was affected 
by pre-treatment with steroid. Therefore cells were either treated for 24 hrs with 10
-8
 M 
dexamethasone or mometasone. On the second day the culture medium was replaced and new 
steroids added for additional 24 hrs. The treatment protocol day1 – day2 was either: a single  
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Figure 3: (A) The effect of serum starving (0.1% FCS), serum stimulation (5% FCS) and 
steroid treatment (dex = 10
-8
 M dexamethasone; mom = 10
-8
 M mometasone) on the 
expression of GR mRNA determined by RT-PCR over a period of 24 hours. Each data point 
represents the mean ± S.E.M. of five fibroblast lines. (B) The expression of C/EBP- encoding 
mRNAs was determined in the same cDNA preparations used in panel A. (C) The expression 
of p21
(Waf1/Cip1)
 encoding mRNAs was determined in the same cDNA preparations used in 
panel A. (D) Representative immuno-staining for the effect of 10
-8
 M dexamethasone (dex) or 
10
-8
 M mometasone (mom) on the expression and cell compartmental localisation of C/EBP- 
(24 hours) and p21
(Waf1/Cip1)
 (24, 48 hours) in sub-confluent serum stimulated (5% FCS) 
fibroblasts. Similar results were obtained in three additional cell lines. 
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dose of dexamethasone or mometasone for 48 hrs, or dexamethasone (24 hrs) followed by a 
medium change with fresh dexamethasone (24 hrs), and similarly for the combinations: 
mometasone / mometasone, or dexamethasone / mometasone, or mometasone / 
dexamethasone. Thymidine incorporation was determined at day1 and day2 during the last 8 
hrs of cell culture. As shown in figure 4B dexamethasone treatment had a short lasting anti-
proliferative effect, 
while mometasone under all circumstances was stronger anti-proliferative drug. The results 
also indicate that mometasone did not deplete the GR as it had an additive effect when given 
twice or was followed by dexamethasone; furthermore, RU486 inhibited this effect (data not 
shown). 
As reported earlier (21) in details dexamethasone reduced extracellular matrix deposition 
in the absence of serum and increased the stimulating effect of serum (figure 4C). 
Mometasone also reduced the deposition of extracellular matrix in the absence of serum, but 
did not further increase its synthesis and deposition in the presence of serum (figure 4C). The 
inhibitory effect of both steroids was mediated by the GR as it could be inhibited when cells 
were pre-treated with RU486 30 min prior to steroid addition (figure 4C). We further 
investigated the effect of the two steroids on extracellular matrix metabolism assessing the 
expression and activity of major gelatinases MMP-2 and MMP-9 in the cell culture medium 
of steroid treated and un-treated cells at 12, 24, 36, and 48 hrs after addition of the drugs. 
None of the two steroids affected the expression or activity of MMP-2 or MMP-9 within 48 
hrs (figure 4D).  
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Figure 4: (A) The effect of repeated steroid treatment on serum induced (5% FCS) fibroblast 
proliferation over 48 hours. (B) The effect of the alternated treatment of dexamethasone (dex) 
with mometasone (mom) and the role of GR depletion by a short acting steroid 
(dexamethasone) on proliferation. (C) The involvement of the GR in dexamethasone (dex) and 
mometasone (mom), both 10
-8
 M, on serum (5% FCS) induced deposition of extracellular 
matrix by lung fibroblasts (n = 3) at 48 hours. For all experiments presented in graphs A-C, 
bars represent the mean ± S.E.M. calculated for at least independent fibroblast lines, and 
each experiment was performed in triplicate; and RU486 was used at a concentration of 10
-6
 
M and cells were 30 minutes pre-incubated before the addition of the first steroid. * indicates 
a statistic significant difference with p < 0.05 comparing the effect of dexamethasone (10
-8
 M) 
to that of mometasone (10
-8
 M) by paired, two tailed student’s t-test. (D) A representative 
gelatine zymography of the effect of 10
-8
 M dexamethasone (dex) or mometasone (mom) on 
the expression and activation of the gelatinases MMP-2 and MMP-9 by human lung 
fibroblasts. Similar results were obtained in two additional fibroblast lines. 
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3.2.5 DISCUSSION 
In this study we demonstrate that mometasone, compared to dexamethasone, has a 
stronger and prolonged anti-proliferative effect in vitro on primary human lung fibroblasts, 
vascular and bronchial airway smooth muscle cells. In fibroblasts the prolonged effect 
correlates with a extended activation of the GR and a long lasting induction of C/EBP-α and 
the anti-proliferative protein p21
(Waf1/Cip1)
 by mometasone at therapeutic achievable 
concentrations. The decrease of GR expression after steroid treatment was due to the 
inhibition of de novo mRNA synthesis and to proteosomal degradation of the GR protein. 
However, the degradation of the nuclear GR was significantly delayed when stimulated with 
mometasone compared to dexamethasone and may therefore reduce the occurrence of 
tachyphylaxis. Furthermore, we provided evidence that different from other steroids 
mometasone does not increase extracellular matrix accumulation in the presence of serum 
(inflammation). 
 
In agreement with others our data showed that the GR was expressed by serum starved 
growth arrested fibroblasts and accumulated on the cytosolic side of the nuclear membrane. In 
absence of steroids the GR travels without DNA-binding throughout the cell, but does not 
bind to the glucocorticoid response element (GRE) consensus sequence (31). In our 
experiments mometasone induced a fast and prolonged activation of the GR compared to 
dexamethasone. This observation is to a certain extend opposing an earlier study which 
reported no significant differences of the activation of the GR compared to another steroid, 
but suggested that mometasone activates the mineralocorticoid and progesterone receptors in 
addition (32). However, there are other additional mechanisms by which mometasone could 
achieve its specific profile of effects as it inhibits the action of other transcription factor 
including AP-1 and NF-κB (12-15). We have reported earlier that the anti-proliferative effect 
of steroids in lung fibroblasts involves the action of the transcription factor C/EBP-α which 
subsequently activates the expression of the cell cycle control protein p21
(Waf1/Cip1)
 (33). Our 
data shows that mometasone induced a similar kinetic as dexamethasone for the activation of 
C/EBP-α, however, it may induce a longer lasting availability as the synthesis of C/EBP-α  
mRNA was prolonged by three hours. Thus the extended activation period of the GR together 
with the availability of active C/EBP-α would extend the time frame in which both factors 
could form the complex which is essential to induce p21
(Waf1/Cip1)
 expression. Such an effect 
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would be similar to the mechanism that we described earlier for the interaction of long acting 
β2-agonists with steroids (19). Indeed the nuclear accumulation and therefore the activation of 
p21
(Waf1/Cip1)
 was extended by mometasone treatment compared to dexamethasone, suggesting 
a longer anti-proliferative effect of mometasone. 
Steroid induced down-regulation of the GR, tachyphylaxis, has previously been described 
for cortisol, prednisone, dexamethasone, fluticasone and budesonide in various cell types (34-
37). The degradation of the GR after stimulation with a steroid, including mometasone is due 
to proteosomal protein degradation as it was significantly reduced by the proteasome inhibitor 
MG132 or when ubiquitination was inhibited (25,38). However, the kinetic of GR down-
regulation may be cell type specific or depend on cell culture conditions. In COS-1 and Hela 
cells dexamethasone-induced degradation of the GR involved ubiquitination and 
disintegration by proteasome 26 (25). Similarly, in this study, dexamethasone treatment of 
human lung fibroblasts significantly decreased the abundance of the GR that was overcome 
by the proteasome inhibitor MG132. This effect did not affect total GR expression, but 
specifically the GR accumulation in the nucleus (25). In contrast to dexamethasone, 
mometasone did not down-regulate the nuclear accumulation of the GR over 24 hrs. This 
difference of mometasone can not be explained by its 12 x stronger binding affinity to the GR 
as in fact the nuclear signal of the GR appeared to be stronger at early time points in the 
presence of dexamethasone. The prolonged activation of the GR by mometasone could be an 
important feature mediating its prolonged anti-proliferative effect. 
In human lung tissue, including human lung fibroblasts GR tachyphylaxis has not been 
studied, yet. In this study we demonstrated that normal non-transformed human lung 
fibroblasts are susceptible to GR tachyphylaxis, but the strength of this effect depends on the 
steroid used. Drug specific differences in nuclear retention of agonist-activated GR have been 
described comparing GR-GRE complexes induced by various synthetic steroids, but not for a 
long acting synthetic steroid such as mometasone (31, 39, 40). Trypsin digestion of such 
steroid-ligated GRE complexes showed distinct degradation products indicating drug-induced 
alterations of the complex with the consequence of different enzyme sensitivity and therefore 
distinct stability (41). Our data indicate that the ligand‘s property may change the structure of 
the GR-GRE complexe, thereby modifying its sensitivity to degradation in the nucleus. Either 
this effect or a stronger steroid-GR binding could confer a protection of the protein-DNA 
complex from endoplasmatic reticular and cytosolic proteasome degradation (42). In this 
context, we showed that the anti-proliferative effect of mometasone is resistant to depletion of 
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the steroid by wash out experiments which again indicated a difference in the complex formed 
by the mometasone with the GR and the GRE. Furthermore, the prolonged and stronger anti-
proliferative effect of mometasone was also observed in pulmonary vascular smooth muscle 
cells and bronchial smooth muscle cells indicating a general rather than a cell type specific 
effect. 
We also observed a significant difference for the re-synthesis of the GR after activation 
by dexamethasone compared to mometasone. When treated with dexamethasone the signal for 
the GR mRNA declined after 6 hrs and stayed at low level over 24 hrs. In contrast, when 
fibroblasts were treated with mometasone the mRNA for the GR increased after an initial 
decline and was above serum stimulated levels at 24 hrs, indicating that mometasone did not 
reduce GR re-synthesis, and therefore thachyphylaxis may be reduced or counterbalanced. 
The anti-proliferative effect of short acting steroids involves the activation of C/EBP-α, 
which forms a complex with the active GR which seems to be essential for the subsequent 
expression of the cell cycle inhibitor p21
(Waf1/Cip1)
 (33, 43). This mechanism seems also to be 
apply for the anti-proliferative action of mometasone, but with a drug specific extended 
expression and activation phase of both C/EBP-α and p21(Waf1/Cip1), which may explain the 
prolonged anti-proliferative action of mometasone. 
Lung remodelling in asthma and COPD not only depends on the proliferation of (myo-) 
fibroblasts and airway smooth muscle cells; it also includes the deposition of extracellular 
matrix by the same cell types (2-4, 18). Surprisingly, only few studies investigated the effect 
of steroids and other anti-asthmatic drugs on this aspect. Unfortunately their results were 
contradictory and can hardly be compared as the drugs used in each study were different, and 
the period of treatment and dosage were not identical (44-49). However, we have shown in 
fibroblasts that several steroids have a dual effect of extracellular matrix deposition and turn 
over (21). When confluent cell layers of human lung fibroblasts were treated with a steroid 
alone in the absence of serum the deposition of extracellular matrix and collagens was 
significantly reduced, while when the steroid was given in the presence of 5% serum it further 
increased the synthesis and deposition of the extracellular matrix and collagens (21). Here we 
demonstrate that mometasone has a different effect on extracellular matrix deposition, as in 
contrast to dexamethasone it did not increase serum stimulated extracellular matrix 
deposition. However, whether this effect will reflect in a beneficial reduction of airway wall 
thickening has to be proven in clinical studies. In addition we provide data that implies that 
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the effect of steroids, including mometasone, on the turn over of the extracellular matrix does 
not involve the action of gelatinases MMP-2 or MMP-9. 
In conclusion we found that mometasone was a more potent inhibitor of cell proliferation 
and keeps the GR for a prolonged period activated. Potentially these differences are caused by 
reduced or absent tachyphylaxis of the glucocorticoid receptor after treatment with 
mometasone. Our findings might be relevant for therapy of inflammatory lung diseases with 
high dose or repeated steroids. 
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Chapter 4 
The long acting effect of ciclesonide on mesenchymal cells depends on its 
activation by epithelial cells 
Ciclosonide is a very effective long acting glucocorticoid which has been introduced to 
therapy of asthma. Clinical studies have shown that a single inhalation of ciclesonide per day 
is sufficient to control asthma. Ciclesonide as such carries a butyl-ester group and cannot bind 
to the GR directly, only after partial digestion by esterases its active metabolite desisobutyryl-
ciclesonide is formed. Only this active metabolite of ciclesonide can bind to the GR and has 
been shown to activate the same signaling pathway as the classical steroids. In the bronchi, 
ciclesonide gets in contact to esterase synthesized by airway cells and is thus activated at the 
lung. It is un-known if any other cell type beside epithelial cells of the lung are capable to 
activate ciuclesonide. Furthermore, the esterfication of ciclosonide is a revertible process, thus 
the butyl-group can be exchanged by longer fatty acids creating a more lipophilic cellular 
stock of the drug within the cell. Such an effect could modify the bio-availability of 
ciclesonide and therefore its time of action.  
 
4.1 OBJECTIVES: 
1.  Does ciclesonide induce a long activation of the GR compared to other long acting and 
short acting glucocorticoids? 
2.  Does the active metabolite of ciclesonide induce a long acting activation of the GR? 
3.  Which cell types of the human lung can metabolize/activate ciclesonide into its active 
form?  
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4.2 The long acting effect of ciclesonide on mesenchymal cells depends on its 
activation by epithelial cells 
 
4.2.1 Summary:  
Long term therapy with inhaled glucocorticoids in asthma often results in reduced drug 
response, due to reduced expression of the glucocorticoid receptor. Long acting 
glucocorticoids were developed to overcome such side effects. In asthma therapy 
glucocorticoids reduce the secretion of pro-inflammatory mediators and airway remodelling. 
Here we investigated the effect of ciclesonide and its active metabolite on glucocorticoid 
receptor activation and on cell proliferation, of bronchial smooth muscle cells. The 
cicelsonide metabolite-1, budesonide or fluticasone activated the glucocorticoid receptor fast 
and with a short duration of the active phase, Non-metabolised ciclesonide had neither a 
significant effect on glucocorticoid receptor activity nor did it inhibit cell proliferation. The 
kinetic of the glucocorticoid receptor activation by the ciclesonide metabolite was similar to 
that of classical glucocorticoids. Co-culture experiments of bronchial smooth muscle cells 
together with epithelial cells revealed that ciclosonide was converted into its active form by 
epithelial cells and that it than was inhibiting the proliferation of bronchial smooth muscle 
cells. Furthermore, in the co-culture system the glucocorticoid receptor was activated for 
extended periods in bronchial smooth muscle cells. All inhibitory actions of the ciclesonide 
metabolite or ciclesonide in the co-culture system could be blocked by pre-incubation of the 
cells with RU486 indicating that the drug‘s mode of action is mediated via the glucocorticoid 
receptor. In summary our data indicate that the molecular mechanism underlying the long 
lasting effect of ciclesonide depends on its metabolisation by epithelial cells and the action of 
its active metabolite is not different from that of classical glucocorticoids. 
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4.2.2 Introduction 
Glucocorticoids act via binding to their intracellular glucocorticoid receptor (GR) which 
is activated, dimerizes, and translocates into the nucleus where it acts as transcription factor. 
The GR also achieves a part of its effects through its interaction with other transcription 
factors, such as C/EBP-α, C/EBP-β, Stat3/5, NF-κB, or AP-1. Most of these transcription 
factors have been shown to be involved in the control of cell proliferation (Rogatsky and 
Ivashkiv, 2006c;Bruna et al., 2003;Zhang et al., 1997;Floyd and Stephens, 2003;Aljada et al., 
1999;Gotoh et al., 1997;Adcock et al., 1996a;Borger et al., 2002;Cha et al., 1998).  
Glucorcoiticoids are most potent and consistently effective in reducing airway 
hyperresponsiveness, improving lung function and decreasing symptom severity (Georgitis, 
1999). Inhaled glucocorticoids such as fluticasone and budesonide are frequently used to 
control symptoms in moderate to severe asthma (Edmonds et al., 2002). The continuous use 
of high dose glucorcoticoids, however, can result in severe side effects—impaired growth in 
children, decreased bone mineral density, skin thinning and bruising, and cataracts. (Rosen 
and Miner, 2005;Dahl, 2006). Various glucocorticoids are known to activate the GR and their 
potency has been established looking at side effects or binding capacity to the GR (Umland et 
al., 2002;Newton, 2000). Little is known about the duration of GR activation by various 
glucocorticoids after in vivo and in vitro application (Umland et al., 2002). 
The potential advantage of ciclesonide over ―classical‖ steroids is its long action. Clinical 
studies showed that for treatment with ciclesonide a single inhalation per day is sufficient to 
control asthma (Kanniess et al., 2001;Pearlman et al., 2005). Different from glucocorticoids 
such as budesonide or fluticasone, the drug ciclesonide carries a butyl-ester group which 
keeps it in a conformation that does not function as an active glucocorticoid. Ciclesonide is 
activated after in halation locally by enzymatic partial digestion by esterases which form its 
active metabolite, desisobutyryl-ciclesonide (des-CIC) (Furthwängler et al., 2002;Silvestri et 
al., 2006;Reynolds and Scott, 2004). In the bronchi, ciclesonide gets in contact to esterase 
synthesized by airway cells and is thus activated at the lung area which is mainly affected by 
the inflammation during an asthma attack. Interestingly, esterfication of a glucocorticoid is a 
revertible process, thus the butyl-group can be exchanged by longer fatty acids creating a 
more lipophilic cellular stock of the drug within the cell and such a process would re-create 
the inactive form of ciclesonide intracellular, which might further contribute to its extended 
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bio-availability (Edsbäcker and Brattsand, 2002;Reynolds and Scott, 2004). It is assumed as a 
beneficial effect of ciclesonide that the portion of the inhaled drugs that precipitates in the 
pharynx wall, and thus is swallowed, is considered to be inactivated as it is digested in the 
liver (Furthwängler et al., 2002). Finally, des-CIC is converted into a series of inactive 
metabolites that are eliminated from the body (Hansel et al., 2006;Peet et al., 2005;Ukena et 
al., 2006b;Silvestri et al., 2006).  
The only other synthetic glucocorticoid that is known to be a metabolite of esterases is 
budesonide (Edsbäcker and Brattsand, 2002). However, in contrast to ciclesonide, budesonide 
is applied as the active, non-esterized form (Edsbäcker and Brattsand, 2002). However, in the 
treatment of persistent asthma ciclesonide has been shown to be more effective compared to 
budesonide (Ukena et al., 2006a). Epithelial cells are suggested to be the main source of 
esterases and synthesis and activation of esterases by other human lung cells such as 
fibroblasts or smooth muscle cells is speculative (Edsbäcker and Brattsand, 
2002;Furthwängler et al., 2002;Christie, 2004;Silvestri et al., 2006) . 
Therefore in this study we assessed the duration of the GR by ciclesonide and its active 
metabolite in human epithelail cells, fibroblasts and bronchial smooth muscle cells. We 
determined the anti-proliferative efficacy of both compounds and their effect on extracellualar 
matrix deposition as an indicator for tissue remodeling. In addition we investigated the role of 
epithelial cells on the activation of ciclesonide in a co-culture system. 
 
4.2.3 Methods 
All chemicals were from Calbiochem (Ca, USA) unless otherwise stated. RU486 was from 
Russel-Uclaf, France, Budesonide from AstraZeneca (Sweden), fluticasone from 
GlaxoSmithKline (UK), ciclesonide and ciclesonide metabolite I from Altana, Germany. 
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Cell culture: Primary human lung fibroblasts, bronchial smooth muscle cell (BSMC) and 
epithelial cell cultures were established from human lungs obtained from patients undergoing 
lobectomy for therapeutically reason as described earlier in details (Johnson et al., 
2001;Tamm et al., 2001). All drugs were solubilized in DMSO (Merck, Darmstadt) and 
further diluted using RPMI/0.3 % albumine as potential carrier for lipophilic glucocorticoids. 
Drug solutions were not further sterile filtered.  
Bronchial smooth muscle cell culture: Primary cultures of human BSMC were grown from 
airway muscle bundles obtained from 4 probands. Cells were grown in RPMI (Seromed) 
containing 10 % fetal calf serum (FCS, Invitrogen), and 20 mM HEPES (Seromed). All 
experiments were performed between passages 3 – 6. Prior to experiments, cells were serum 
starved for 48 hours using RPMI-1604 containing 0.1 % FCS. No antibiotics were used at any 
time. 
Epithelial cell culture: Primary cultures of human bronchial epithelial cells (BEC) were 
established form brushings of the epithelium cell layer from 4 patients. Cells were grown in 
epithelial cell medium (Cambrex, Netherlands) supplemented with insulin, T4, cortisol, 
bovine pituitary gland extract, and insulin according to the instructions of the manufacturer 
(all Cambrex). Primary cell cultures were performed on lysine coated cell culture dishes (BD 
BEC cultures were propagated by trypsination, and cells were transferred into collagen I / 
fibronectin (80 µg/cm
2
) coated cell culture dishes (BD) or cover glass plates (VWR 
international AG, Switzerland). Prior to experiments cells were starved for 48 hours in cortisol 
free epithelial medium. No antibiotics were used at any time. 
Nuclear and cytosolic extracts: Cytosolic extracts were prepared from 80 % confluent cells 
resuspended in low salt buffer [20 mM Hepes (pH 7.9), 10 mM KCl, 0.1 mM NaVO4, 1 mM 
EDTA, 1 mM EGTA, 0.2 % NP-40, 10 % glycerol, Complete protease inhibitor (Roche 
Diagnostics, Switzerland)] and incubated for 10 min on ice. After centrifugation for 1 min. at 
13‗000 x g (4oC) supernatants were taken as cytosolic fraction. The remaining pellet was 
dissolved in 50 µl high salt buffer (420 mM NaCl, 20 mM Hepes (pH 7.9), 10 mM KCl, 0.1 
mM NaVO4, 1 mM EDTA, 1 mM EGTA, 20 % glycerol, Complete
TM
 protease inhibitor) and 
samples were kept on ice for 30 min, followed by a centrifugation step at 13‗000 x g for 10 
min (4 
o
C). Supernatants were taken as nuclear fraction (Eickelberg et al., 1999). Protein-
concentration was measured according to Bradford's method (Biorad). 
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Western Blot: To determine expression of GR protein 5-15 µg total protein were size-
fractionated in a denaturing 4-15 % SDS- polyacrylamide gel electrophoresis. After 
electrophoresis, proteins were transferred onto PVDF membrane (Millipore Corp., MA, USA) 
by a semi-dry transfer. Membranes were blocked for 1 hour (10 mM Tris, 150 mM NaCl, 0.05 
% Tween 20, 5 % skimmed milk) and incubated with polyclonal antibodies specific for GR 
(E20, Santa Cruz) at 4°C over night, followed by incubation with 2
nd
 HRP-linked anti-rabbit 
antibody (cat# AP160B, Chemicon) for 30 min. Protein bands were detected by enhanced 
chemiluminescence (ECL, Pierce, IL, USA).  GR expression in all samples was done by 
scanning of X-ray films. Optical density (OD) of GR-signals was evaluated by using AIDA 
2.0 and ImageJ Ver 1.32c. Western blots were normalized according to Eschenhagen et al. 
(Eschenhagen et al., 1992).  
Electrophoretic mobility shift assay (EMSA): DNA binding proteins were characterized by 
EMSA using a [
32
P]-labelled GRE oligonucleotide (ABR). Binding conditions: NaCl 20 mM, 
KCl 60 mM, MgCl2 5 mM, DTT 20 mM, dIdC 1µg/µg nuclear extract, 1 µg BSA/µg nuclear 
extract, and incubation was carried out for 30 min. at 21 °C. DNA/protein complexes were 
analysed on a non-denaturing 6 % polyacrylamide gel, and exposed to a phosphor imager 
screen. Specificity of the observed DNA/protein complexes was characterised by pre-
incubating the extracts with a 50 fold excess of unlabeled GRE. 
Immunohistochemistry: Cells were grown on cover slips (VWR). After treatment, cover 
slips were rinsed with ice-cold phosphate buffered saline (PBS; 5 min.) and fixed with 4% 
formaldehyde at room temperature (20 min.). If not otherwise stated, all chemicals were from 
Sigma (Buchs, Switzerland). After washing twice with PBS, slides were placed in a humid 
chamber and unspecific binding was blocked (coat of PBS, 5 % goat serum, 0.3% Triton-X-
100) and incubated for 1 hour at room temperature. Then, slides were incubated at 4 °C with 
polyclonal rabbit anti-GR antibodies (sc-1003, Santa Cruz Biotechnology) diluted 1:200 in 1 
% goat serum in blocking buffer overnight. After two further washes with PBS, slides were 
incubated with 150 µl of Cy3 labelled goat anti-rabbit antibody (Jackson Immuno Research 
Laboratories, Inc; 1:300 dilution in 1 % goat serum blocking buffer) and incubated at room 
temperature (1 hour), in a dark and humid chamber. Stained slides were then washed twice 
with PBS and twice (5 minutes) with distilled water before being embedded in Fluorsave
TM
 
(Calbiochem). Images were captured using confocal imaging at 543 nm, LP 585 nm (Zeiss, 
Jena, Germany). For all pictures analysed, same acquisition settings were used. To avoid 
influence of photo bleaching, areas were searched using light microscopy and pictures were 
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then directly taken using confocal laser microscopy. Stacks were opened in ImageJ Ver. 1.32c 
and nuclear staining was measured in the stack with the strongest signal. 
[
3
H]-Thymidine incorporation: PDGF or FCS-induced cell proliferation was determined by 
[
3
H]-thymidine incorporation. [
3
H]-thymidine incorporation was determined in 60-80 % 
confluent cells that had been serum-deprived previously for 36 hrs (0.3 % albumine, 
exchanged every 12 hrs) followed by PDGF (10 ng/ml) or FCS (5%) stimulation for 24 hrs in 
the presence or absence of either glucocorticoid. Ru486 was from Roussel Uclaf 
(Romainville, France), MG 132 was from Calbiochem. After treatment, drugs were not 
removed until cells were harvested. Five µCi/ml [
3
H]-thymidine (Amersham, Little Chalfont, 
UK) were added to culture medium for the last 8 hrs. Cells were harvested on glass fiber 
paper (GF/C-Unifilter, Canberra Packard Instruments, Meriden, CT, USA) using an automatic 
cell harvester (Filtermate 186, Canberra Packard Instrument). Incorporated radioactivity was 
measured with a liquid scintillation counter (Topcount, Canberra Packard Instruments) and 
values were displayed and analysed as counts per minute (cpm).  
For Co-culture experiments, mesenchymal cells were cultured in 6 well transwell plates 
with a layer of A549 cells in the Transwell. Steroid was added to the transwell. Before 
harvesting, A549 cells were removed. Cells were washed 3 times with PBS followed by cell 
lysis using 0.3 M NaOH and liquid scintillation counting. 
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4.2.4 Results: 
Ciclesonide is a weak activator of glucocorticoid receptor activation 
Compared to other steroids such as budesonide and fluticasone, ciclosonide is a weak 
stimulator of the glucocorticoid receptor (figure 1). Budesonide and fluticasone induced a 
complete depletion of the glucocorticoid receptor signal from the cytosol and shifted the 
glucocorticoid receptor into the nucleus within 30 minutes. Fluticasone, induced the fastest 
and strongest accumulation of the glucocorticoid receptor in the nuclear protein fraction, but 
the signal also weakened fastest in the presence of flucticasone (figure 1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 First line describes the time point of cell harvesting. Lanes indicate: Ctr – starving medium, 
Ci – ciclesonide, Bud – budesonide, Flu – fluticasone, P – PDGF, CM1 – ciclesonide metabolite I. All 
drugs were used at 10-8 M. The arrow depicts the specific band of the GR. 
 
In contrast, only a slight increase of the glucocorticoid receptor in the nuclear protein fraction 
was seen in the presence of ciclesonide after 1 hour.  
 
As shown in figure 1B. The cilcesonide metabolite-1 was a strong activator of the 
glucocorticoid receptor. The shift of the glucocorticoid receptor from the cytosol into the 
nucleus was complete after 30 minutes and was stronger than the effect of busdesonide or 
fluticasone at the same concentration. The ciclesonide metabolite-1 induced nuclear 
accumulation of the glucocorticoid receptor followed a similar kinetic as that of budesonide 
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(figure 1). However, after 24 hours the signals of the glucocorticoid receptor signal in all 
steroid treated cells was completely reduced and reach back ground level in both cellular 
compartments (figure 1). 
    
We have described earlier that cell density and specifically the presence of a general pro-
inflammatory factor such as serum modifies the bio-availability of the glucocorticoid 
receptor. Therefore we tested the effect of 5% FCS on the activation of the glucocorticoid 
receptor by  
 
Figures 2, Incubation of ASMC with ciclosonide metabolite 1 induced a shift of GR from the cytosol 
to the nuclear compartment. ASMC cultures with 0.1% and 10%FCS.First line describes the time 
point of cell harvesting. Lanes indicate: Ctr – starving medium, P – PDGF, CM1 – ciclesonide 
metabolite I.  All drugs were used at 10(-8) M. The arrow depicts the specific band of the nuclear GR 
and cytosolic GR. 
 
steroids. As shown in figure 2, serum induced a rapid increase of the glucocorticoid receptor 
within 30 minutes in both the cytosol and the nucleus. Due to the strong effect of serum alone 
we could not determine any additional increase of the glucocorticoid receptor signal in the 
presence of steroids at early time points. Interestingly the cytosolic glucocorticoid receptor 
signal increased in the presence of the ciclesonide metabolite-1 at 30 minutes and 1 hour after 
drugs addition (figure 2). At three and six hours the signal of the glucocorticoid receptor in 
the nucleus was significantly stronger when the cells were stimulated with the ciclesonide 
metabolite-1 compared to control cells and of cells that had been stimulated with PDGF-BB, 
however this effect disappeared at 24 hours (figure 2). The total amount of glucocorticoid 
receptor however, did not diminish after steroid treatment in the presence of serum, a finding 
that is in line with our earlier study on the effect of serum on glucocorticoid receptor 
expression in lung fibroblasts. 
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The activation of the glucocorticoid receptor was also determined by immuno 
histochemistry and confirmed the drug specific effect on glucocorticoid receptor activation. 
We already described above that ciclesonide has to be converted into its active metabolite by 
the action of esterases. Epithelial cells are considered as the major source of estareses in the 
lung. Therefore we first determined the activation of the glucocorticoid receptor by 
ciclesonide in epithelial cells using immuno-histochemistry, and compared the activation of 
the glucocorticoid receptor to budesonide and fluticasone The Epithelial cells were starved in 
steroid free medium for 12 hours before addition of the respective steroids at 10
-8
 M. In 
untreated cells, the GR is mainly located in the cytosol. Fluticasone or budesonide let to rapid 
translocation of the GR into the nucleus of the cells within 10 to 30 minutes. In contrast, 
ciclesonide treatment did not lead to GR translocation before six hours. After 24 hours 
treatment, it is no different on the GR translocation with budesonide, fluticasone and 
ciclesonide all at 10
-8
M in epithelial cells. Treatment of epithelial cells with ciclesonide leads 
to a slow activation of the GR when compared to that stimulated by either budesonide or 
fluticasone. This finding suggests that primary human bronchial epithelial cells are effectively 
activating by a slow metabolism of ciclesonide into its active metabolite (figure 3). 
 
The functional activation of the glucocorticoid receptor by ciclesonide metabolite-1  
Next we assessed whether the nuclear accumulation of the glucocorticoid receptor was 
paralleled by its increased binding affinity to its consensus DNA sequence the glucocorticoid 
response element, GER. Using electrophoretic mobility shift assay (EMSA) with the GRE 
sequence as a binding target for the glucocorticoid receptor we were able to demonstrated that 
all steroids induced a fast activation and DNA binding activity of the glucocorticoid receptor. 
Budesonide and fluticasone led to activation of the GR as fast as 30 minutes after treatment. 
GR activated by fluticasone reached its peak as early as 30 to 60 minutes and declined at 6 
hours. Ciclesonide metabolite-1 was able to mediate a persistent GR activation over 24 hours. 
Budesonide-mediated GR activation lasted for up to 6 hours. But at 24 hours GR activity was 
about 20 % higher in ciclesonide metabolite-1 treated cells compared to budesonide. In the 
cytosolic fraction, glucocorticoid treatment led to a slight increase in the presence of activated 
GR of airway smooth muscle cells. This was measurable over 24 hours. However, since 
activated GR is rapidly transferred into the nucleus, detection of activated GR within the 
cytosol is close to the detection level of EMSA (figure 4). 
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Figure 3: Immunohistochemistry of primary human bronchial epithelial cells detecting the 
GR. Cells were treated 24, 6, 1 hour or 10 minutes before harvesting as indicated. Untreated 
cells served as control. Red colour depicts the GR, the nucleus was stained with To-RPO3, 
depicted in blue. Bud – budesonide, Flu – fluticasone, CIC – ciclesonide, all at10-8 M  
 
Effects of steroid treatment on bronchial smooth muscle cell proliferation 
Bronchial smooth muscle cells were treated with various glucocorticoids to protect 
against platelet-derived growth factor- (PDGF-) induced cell proliferation or glucocorticoid 
pre-treatment of resting cells to inhibit PDGF-induced cell proliferation, as two methods to 
investigate the steroid anti-proliferative ability in bronchial smooth muscle cell proliferation. 
We were measuring [
3
H]-thymidine incorporation as a marker for DNA replication. 
The results showed that RU486 had no effect on cell proliferation between 10
-11
 M and 10
-7
 
M. Dexamethasone at low concentrations (10
-11
 M or 10
-10
 M) increased cell proliferation 
before dexamethasone became antiproliferative at 10
-7
 M. Both, budesonide and fluticasone 
were more potent in the inhibition of cell proliferation, leading to significant inhibition of dell 
proliferation between 10
-10
 M (fluticasone) and 10
-9
 M (budesonide). In contrast, ciclesonide 
Flu
CIC
10 minutes 60 minutes 360 minutes 24 hours
Ctr
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was not able to inhibit cell proliferation unless at concentrations > 10
-8
 M. To indicate 
glucocorticoid dependency of the inhibition of cell proliferation, RU486 (10
-7
 M) inhibited 
dexamethasone induced cell proliferation (figure 5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Electrophoretic mobility shift assay (EMSA) using nuclear or cytosolic extracts of bronchial 
smooth muscle cells after treatment. Time points are indicated in the first line. In contrast to Western 
blot, EMSA is able to distinguish between activated GR and non-activated GR. Thus, nuclear GR 
signal (a) is 10-100 fold stronger than in cytosolic extracts (b).  
 
To investigate whether bronchial smooth muscle cells are able to convert ciclesonide into its 
active metabolite and how washing the cells influence the anti-proliferative properties of 
steroids. Cells were incubated for 12 hours with steroids removed thereafter. Subsequently, 
cell proliferation was stimulated using 5 % FCS. At high concentrations, ciclesonide and 
ciclesonide metabolite-1 appeared to be more potent than dexamethasone, budesonide or 
fluticasone. There was no significant difference between ciclesonide and its active metabolite. 
This indicates that bronchial smooth muscle cells were able to convert ciclesonide into its 
active form within the 12 hours of pre-incubation, thus ciclesonide treated cells were growth 
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arrested when cells became FCS-stimulated. Interestingly, fluticasone and budesonide could 
be washed away much more easily than ciclesonide or ciclesonide metabolite-1. (Figure 6). 
Bronchial smooth muscle cells were able to convert ciclesonide into its active form within the 
12 hours of pre-incubation. Ciclesonide and ciclesonide metabolite-1 seem to persist longer 
within the cell than fluticasone and budesonide or are stronger bound to cell culture plastic or 
lipophilic cellular compartments. 
 
Figure 5: Thymidine incorporation of BSMCs after removal of the respective steroids. Cells 
were treated with either dexamethasone (Dexa), ciclesonide (Ci), budesonide (Bud) or 
fluticasone (Flu) at the concentrations indicated. RU486 (mifepristone, an antiglucocorticoid) 
was used as non-GR activating steroid (10
-7
 M). Dexa&Ru indicates combined treatment of 
Ru486 (10
-6
 M) and dexamethasone (10
-7
 M). To avoid esterase contamination, cells were 
stimulated with platelet derived growth factor BB (PDGF), a cytokine known to be a strong 
inducer of BSMC proliferation (Carlin et al., 1999).  
At high concentrations, ciclesonide and ciclesonide metabolite I appeared to be more potent 
than dexamethasone, budesonide or fluticasone. At 10-8 M, budesonide and fluticasone were 
not active at all. There was no significant difference between ciclesonide and its active 
metabolite. This indicates that BSMC were able to convert ciclesonide into its active form 
within the 12 hours of preincubation, thus ciclesonide treated cells were growth arrested when 
cells became FCS-stimulated. Interestingly, fluticasone and budesonide could be washed 
away much more easily than ciclesonide or ciclesonide metabolite-1. To investigate, whether 
epithelial cells may affect the action of ciclesonide on the proliferation of airway smooth 
muscle cells, cells were treated in the presence of A549, a  human airway epithelial tumour 
cell line. Thymidine incorporation was reduced by 20 % in ciclesonide treated cells without 
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epithelial cells. In the presence of epithelial cells proliferation was reduced by more than 50 
%. Co-culture of airway smooth muscle cells with epithelial cells seems to speed up 
ciclesonide metabolism with subsequent inhibition of airway smooth muscle cell proliferation 
(figure 7). 
 
  
Figure 6: Thymidine incorporation of BSMCs after removal of the respective steroids. Cells 
were treated with either ciclesonide (Cicle), ciclesonide metabolite-1 (MetI), dexamethasone 
(Dexa), budesonide (Bud) or fluticasone (Fluti) at the concentrations indicated. After 12 
hours, medium containing the drugs was removed and cells were stimulated with 5 % FCS for 
24 hours in presence of 
3
H-thymidine. Thus in contrast to the experiments shown in figure 4 
and 6, this experiment lasted for 36 instead of 24 hours.  
 
4.2.5 Discussion  
Inhaled glucocorticoids are the corner stone of the treatment of mild to severe asthma. 
After activated glucocorticoid receptors bind to specific DNA binding site, the GRE thereby 
changing gene transcription of pro-inflammatory cytokines. Besides recruitment of 
inflammatory cells, these cytokines may lead to hyper-proliferation of bronchial smooth 
muscle cells observed in asthma, In contrast to their binding affinity, glucocorticoid potency 
in glucocorticoid receptor activation has not been fully investigated for modern 
glucocorticoids. We have compared the novel glucocorticoid ciclesonide with the most 
common inhaled glucocorticoids budesonide and fluticasone on glucocorticoid receptor 
activation in bronchial smooth muscle cells and their potency on the inhabitation of smooth 
muscle cell proliferation. To investigate, whether ciclesonide provides longer lasting 
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glucocorticoid receptor activation, therefore we investigated the effects of different steroids 
on kinetic of GR translocation and proliferation in human primary bronchial smooth muscle 
cells. 
 
Figure 7: Thymidine incorporation of BSMCs in presence of epithelial cells (transwell 
experiment) BSMCs were subconfluently plated and transwells were installed. Cells were 
stimulated using heat-inactivated 5 % FCS in presence or absence of ciclesonide (Cicle; 10
-8
 
M). After 24 hours, transwells were removed and [3H] thymidine was added to cell culture at 
5µCi/ml for further 4 hours. Ciclesonide was more potent in presence of A549 than without. 
We showed that similar to fluticasone and budesonide, ciclesonide or ciclesonide 
metabolite-1 were in activating and translocation of the GR. The effect of ciclesonide was 
greatly retarded, when compared to ciclesonide metabolite-1, this obviously affected cell 
proliferation, where ciclesonide appeared to be less potent. When cells have been pretreated 
for 12 hours with either drug, we could not observe a difference between ciclesonide and its 
metabolite. This indicates that bronchial smooth muscle cells are slow metabolisers of 
ciclesonide. In presence of epithelial cells, ciclesonide was a more potent inhibitor of serum 
induced cell proliferation, supporting that epithelial cells, present in the human airway, are 
augmenting ciclesonide action on cell growth of bronchial smooth muscle cells. In contrast to 
fluticasone or budesonide, translocation of the GR was slower in bronchial smooth muscle 
cells treated with ciclesonide. Interestingly, GR translocation of ciclesonide metabolite-1 had 
a similar kinetic to fluticasone or budesonide. Same as all glucocorticoids were.  
We conclude that bronchial smooth muscle cells are slow in metabolising ciclesonide and 
thus lead to retarded release of the active metabolite-1. To compare the speed of ciclesonide 
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activation in airway smooth muscle cells and epithelial cells, airway smooth muscle cell 
proliferation was investigated in the absence or presence of an airway epithelial cell line 
(A549). Co-culture with epithelial cells increased inhibition of airway smooth muscle cell 
proliferation. This may be interpreted that the combination of airway smooth muscle cells 
with A549 cells seems to speed up ciclesonide metabolism with subsequent inhibition of cell 
proliferation. This result needed to be confirmed in the primary human epithelial cells. We are 
not sure that primary human epithelial cells have same esterase and activity of A549 cells. 
Physiological relevance of the activation of the glucocorticoid receptor was assessed using 
cell proliferation assay according to two different experimental setups. In the first setup, we 
were measuring the effect of different glucocorticoids on platelet-derived growth factor- 
(PDGF-BB) stimulated cell proliferation, where ciclesonide showed similar efficacy in 
inhibition of airway smooth muscle cell proliferation compared to fluticasone and budesonide. 
But fluticasone (significant inhibition beginning at 10
-10
 M) and budesonide (significant 
inhibition beginning at 10
-9
 M) were more potent than ciclesonide (significant inhibition at 
concentrations of 10
-8
 M and 10
-7
 M). In the second setup of proliferation experiments, the 
steroids were incubated for 12 hours with airway smooth muscle cells; subsequently the 
supernatant was removed before growth stimulation without addition of glucocorticoids. 
Under these conditions, ciclesonide and des-CIC had comparable effects and were more 
potent and effective than budesonide or fluticasone. This implies, that ciclesonide can be 
activated by airway smooth muscle cells within 12 hours and persists longer within the cell 
than fluticasone and budesonide. 
Our data might have some practical implications for the clinical use of ciclesonide. As we 
have shown that ciclesonide needs the activation by epithelial cells its action might be 
significantly delayed in diseases where the layer of epithelial cells is severely damaged, such 
as in COPD. Clinical data suggetes that ciclesonide is beneficial in mild to moderate 
asthmatics, but we may doubt its effect in patients with severe asthma, again due to a 
significant damage of the epithelial cell layer. When we compare the action of ciclesonide as 
a long acting steroid to that of mometasone, our data implies that mometasone is the better of 
both drugs budesonide and Dexametasone. This might be further supported by the observation 
that mometasone did not induce the depletion of the glucocorticoid receptor at 24 hours, while 
the ciclesonide metabolite-1 did, and therefore is not different form classical short acting 
steroids.  
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In conclusion the above data indicate that the molecular mechanism underlying the long 
lasting effect of ciclesonide is not different from that of classical glucocorticoids but depends 
on its activation by epithelial cells. 
This data has been expanded and that it is currently prepared for publication.
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My thesis aimed to determine the effect of inflammation on the expression and function of the 
GR in the human lung using a cell culture model with primary mesenchymal cell types 
including connective tissue fibroblasts and bronchial smooth muscle cells of non-diseased 
human lungs. The thesis also aimed to characterize the mode of action of two novel long 
acting steroids, mometasone and ciclesonide, and to compare their mode of action on cell 
biology.   The highlights of these experiments summarized are: 
1. Cell density and inflammation alter the distribution and function of the GR.  
2. Mometasone does not induce tachyphylaxis and has a preferable effect on airway 
remodelling. 
3. The long lasting effect of ciclesonide depends on its metabolisation by epithelial cells 
4. The activation of ciclosonide metabolite is not different from that of classical     
          glucocorticoids.
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APPENDIX  
MATERIALS AND METHODS  
Primary human lung cell cultures  
The primary human lung cell cultures were established from macroscopically normal 
parts of peripheral lung tissue obtained from patients undergoing partial lung resection as part 
of a lung cancer therapy. This protocol was approved by the Ethical committee of the Faculty 
of Medicine, University Hospital Basel (#M75/97). Tissues were collected from the 
Department of Thoracic Surgery. All patients gave written and informed consent. Primary 
human lung fibroblast cultures are well established in our laboratory and their phenotype was 
previously characterized and described by our group (Roth et al., 1996;Papakonstantinou et 
al., 2000;Papakonstantinou et al., 2003)  
Briefly, fibroblasts were established from sterile lung tissue samples stored at 4°C in 
sterile PBS (Cambrex Bio Science, Verviers, Belgium). Tissue samples were cut into small 
pieces of 1-2 mm3 and 16-20 pieces were placed into 75 cm2 flasks pre-wetted with 5 ml of 
RPMI 1640 (2.1 mM glutamine and 25 mM Hepes; Cambrex) supplemented with 10% FCS 
(heat inactivated for 15 min at 65°C; Gibco BRL Invitrogen, Basel, Switzerland) and 1% 
MEM-Essential minimum vitamins (Cambrex). Cultures were performed without antibiotics 
and were kept at 37°C in a humidified incubator containing 5% CO2. Epithelial-like cells 
started to grow after few days followed by spreading of spindle shape-like fibroblasts from 
the tissue pieces. Medium was changed twice a week until fibroblasts reached confluence 
around the tissue pieces. Then, cells were washed three times with PBS and trypsinized 
[0.125% trypsin (Biochrom AG, Berlin, Germany) and 0.01% EDTA in PBS] for 3 min at 
37°C. For the first passage, cells were re-suspended in 10% FCS medium in the same flask to 
avoid any cell loss and medium was changed the following day. The next passages were 
performed at a 1:3 ratio.  
Fibroblasts displayed a typical spindle-shaped morphology, stained positive for fibronectin 
and laminin but were negative for von Willebrand factor, Factor VIII, cytokeratin, and smooth 
muscle actin. Fibroblasts between passages 3 and 6 were used for all experiments.  
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Primary cultures of human BSMC were grown from airway muscle bundles obtained from 
probands. Cells were grown in RPMI 1640 containing 10 % foetal calf serum, and 20 mM 
HEPES. All experiments were performed between passages 3 – 6. Prior to experiments, cells 
were serum starved for 48 hours using RPMI-1604 containing 0.1 % FCS. No antibiotics were 
used at any time. (Johnson et al., 2001;Johnson, 2001). 
Cell stimulation and drug treatment Serum starvation  
Prior to stimulation and treatment, cells were growth-arrested by serum starvation for 24 
h in low serum RPMI 1640 medium supplemented with 0.1% FCS. Medium was exchanged 
after 12 and 24 h to avoid auto-stimulation of the cells.  
dexamethasone from Calbiochem, Lucerne, Switzerland, budesonide from AstraZeneca, 
Lund, Sweden and ciclesonide and ciclesonide metabolite I from Altana, Germany. 
Experiments at concentrations ranging from 10
-6
 to 10
-10
 M for 24 or 48 h under both non-
inflammatory and inflammatory conditions. Drugs were dissolved in DMSO, which final 
concentration (< 0.01% DMSO in the culture medium) had no effect on all measured 
parameters.   
Total proteins concentration  
Total proteins concentration in conditioned media was measured using the Bradford 
protein assay (Bio-Rad Laboratories GmbH, Munich, Germany). The standard curve was 
established using bovine serum albumin (0-500 ng/ml) and the absorbance was measured at 
595 nm with a microplate reader (SpectraMax 190, Molecular Devices Corporation, 
Sunnyvale, USA).   
RNA extraction and reverse transcription  
Cells were plated in 100 x 20 mm dishes, grown until confluence and serum-deprived for 
24 h prior to stimulation and/or drug treatment. After incubation, cells were washed twice 
with ice- cold PBS, scrapped and cell pellets were collected by centrifugation at 900 x g for 
10 min. Total RNA was isolated using RNeasy Mini kit (Qiagen, Basel, Switzerland) and 
RNA concentration and purity were measured by spectrophotometry (NanoDrop 
Technologies Inc., Wilmington, DE, USA). The A260/A280 ratio was used as an indicator of 
purity with optimal values ranging between 1.8 and 2.0 RNA samples were stored at -70°C 
until analysis. First strand cDNA was synthesized from 1 µg of total RNA using M-MLV 
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Reverse Transcriptase according to the manufacturer‘s instructions (Promega, Madison, WI, 
USA).  
Polymerase chain reaction  
cDNA was amplified using Taq DNA polymerase (Promega). PCR conditions consisted 
on 1) an initial denaturation at 95°C for 2 min, 2) denaturation at 98°C for 20 sec, 
primer annealing at 58°C for 22 sec, and extension at 72°C for 30 sec to 1 min for 20-40 
cycles, and 3) a final extension at 72°C for 5 to 10 min. The intensity of each band was 
analyzed by densitometry using the NIH Image J software and the relative mRNA 
expression of target gene was normalized to 2-microglobulin (2-M). All primers were 
purchased from MWG-Biotech AG (Ebersberg, Germany). The sequence of GR primer: 
forward:5‘-CACCCTCACTGGCTGTCGCTTCTC-3‘, reverse:5‘TGACAAACGAAA 
GAGGAG ACCGCC-3‘, 23 cycles: denaturation: (98°C, 20 sec), annealing (58°C, 22 
sec) and extension (72°C, 30 sec); p21 (primer set, R&D Systems Inc, Minneaplois, 
USA), 30 cycles: denaturation: (94°C, 45 sec), annealing (55°C, 45 sec) and extension 
(72°C, 45 sec); 2-microglobulin (2-M): forward 5‘-CTCGCGCTACTCTCTCTCTT 
TCT3‘,reverse:5‘TTAAGTGGGATCGAGACATGTAAGC-3‘, 23 cycles: denaturation 
(98°C, 30 sec), annealing (60°C, 60 sec) and extension (72°C, 60 sec). PCR products 
were size fractionated by electrophoresis in a 1 % agarose gel and products were 
visualized by ethidium bromide. 
Immuno-histochemistry:  
Fibroblasts were seeded (10
4
 cells/ml) in 24 well plates and serum deprived (24 hrs) 
before being stimulated with 10% FCS in the presence or absence of dexamethasone or 
mometasone fuorate (10
-6 
or 10
-8
M) for 0, 6, 18, 24 or 48 hrs. Cells were washed with 
phosphate buffered saline (PBS; 3 x 5 min), fixated in ice-cold methanol:acidic acid (3:1, 15 
min), and washed twice with PBS. Endogenous peroxidase was blocked (0.1% NaN3, 0.3% 
H2O2; 30 min, room temperature), followed by 2 washes with PBS, and unspecific antibody 
binding was blocked (5 % FCS, 0.5% Tween-20 in PBS; 1 hrs, room temperature). Then 
slides were incubated with a polyclonal rabbit anti-glucocorticoid receptor antibody (sc-1003, 
Santa Cruz Biotechnology, Santa Cruz, CA; 1:400 in blocking buffer‘ 4°C, overnight) before 
being washed twice with PBS and incubated with a horseradish-peroxidase-labelled goat anti-
rabbit antibody (sc-2004, 1:1000 in blocking buffer, 1 hr, room temperature). Slides were then 
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washed with PBS (3 x 5 min) and the developing solution AEC Chromogen Kit (AEC101, 
Sigma, Saint louis, Missouri, USA) was added according to instructions until a red signal was 
obtained in the positive control. Slides were washed twice with deionized water and images 
were captured using Anlysis-D soft imaging system with Olympus IX50 microscope 
(objective 40 x ). The same procedure was performed for p21
(Waf1/Cip1) 
 using a polyclonal 
mouse anti-p21
(Waf1/Cip1) 
antibody (610234, BD Biosciences Pharmingen  San Diego, CA, 
USA) diluted 1:300 in blocking buffer. The secondary antibody was a horseradish-
peroxidase-labelled goat anti-mouse antibody (sc-2005; diluted 1:1000 in blocking buffer) 
incubating the slides for 1 hr at room temperature. 
Nuclear and cytosolic extracts and immuno-blotting: 
Cytosolic and nuclear proteins were prepared from 80 % confluent fibroblasts and the 
protein-concentration was measured according to Bradford's method (Biorad) as described 
earlier (19).Protein expression was determined in 10 µg of total protein that were size-
fractionated in a denaturing 4-15 % SDS-PAGE (19). Proteins were transferred onto PVDF 
membrane (Millipore Corp., MA, USA) and transfer was controlled by Ponceau's staining. 
Membranes were incubated for 1 hr with blocking buffer (10 mM Tris, 150 mM NaCl, 0.05 % 
Tween 20, 5 % skimmed milk), followed by overnight incubation (4°C) with either a 
polyclonal anti-glucocorticoid receptor antibody, an antibody for C/EBP -α , or p21(Waf1/Cip1) 
(sc-8992, sc-61, sc-6246; all: Santa Cruz Biotech). Unbound antibody was washed of (2 x 
blocking buffer) and membranes were incubated (30 min) with a 2
nd
 horseradish-peroxidase-
labelled anti-rabbit antibody (Chemicon). Protein bands were detected by enhanced 
chemiluminescence (ECL, Pierce, IL, USA) exposed to X-ray films. Optical density of 
protein-signals was evaluated by using AIDA 2.0 and ImageJ (19). 
Statistical analysis  
Results of protein activation kinetics were compared by paired ANOVA. The effect of 
signal protein inhibitors and siRNAs were compared by paired two-tailed student‘s t-
test. Results were considered to be significantly different when the probability (p) was < 
0.05. 
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